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Antibodies, the quintessential biological recognition molecules, are not ideal for many 
applications because of their large size, complex modifications, and thermal and chemical 
instability. Identifying alternative scaffolds that can be evolved into tight, specific binding 
molecules with improved physical properties is of increasing interest, particularly for biomedical 
applications in resource-limited environments. Hyperthermophilic organisms, such as Sulfolobus 
solfataricus, are an attractive source of highly stable proteins as starting points for alternative 
molecular recognition scaffolds. We describe the first application of phage display to identify 
binding proteins based on the Sulfolobus solfataricus protein Sso7d scaffold. Sso7d is a small 
(approximately 7 kDa, 63 amino acids), cysteine free DNA-binding protein with a melting 
temperature of nearly 100 °C. Tight binding Sso7d variants were selected for a diverse set of 
protein targets from a 1010 member library, demonstrating the versatility of the scaffold. These 
Sso7d variants are able to discriminate among closely-related human, bovine, and rabbit serum 
albumins. Equilibrium dissociation constants in the nanomolar to low micromolar range were 
measured via competitive ELISA. Importantly, the Sso7d variants continue to bind their targets in 
the absence of the phage context. Furthermore, phage-displayed Sso7d variants retain their binding 
affinity after exposure to temperatures up to 70 °C. Taken together, our results suggest that the 
Sso7d scaffold will be a complementary addition to the range of non-antibody scaffold proteins 
iii 
 
that can be utilized in phage display. Variants of hyperthermostable binding proteins have potential 
applications in diagnostics and therapeutics for environments with extreme conditions of storage 
and deployment. One application for utilizing Sso7d evolved binding molecules is development 
of Tuberculosis (TB) diagnostic tests. TB is the leading cause of death from infectious disease 
worldwide. The low sensitivity, extended processing time and high expense of diagnostics are 
major challenges to the detection and treatment of TB. Mycobacterium tuberculosis ornithine 
transcarbamylase (Mtb OTC, Rv1656) has been identified in the urine of patients with active TB 
infection, making Mtb OTC a promising target for point-of-care diagnostics in resource-limited 
settings. We are motivated to engineer phage-based diagnostic systems that feature improved 
physical stability, cost of production and sensitivity relative to traditional antibody-based reagents. 
Specific binding proteins with low nanomolar affinities for Mtb OTC were selected from the naïve 
Sso7d phage library. Phage particles displaying Sso7d variants along with a monoclonal antibody 
(mAb) generated by hybridoma technology were utilized to generate a capture ELISA-based assay 
for Mtb OTC. The ELISA assay signal is linear over the target concentration range of 2.0-125.0 
ng/mL with limit of detection 0.4 ng/mL (12 pM), which is comparable to commercial available 
antibody-based assays. Importantly, this assay maintains functionality at both neutral and basic pH 
in presence of salt and urea over the range of concentrations typical for human urine. Furthermore, 
towards our phage-based diagnostic test development goal, a test with a pair of phage displaying 
2 different Sso7d variants was established with a limit of detection 4.5 ng/mL (130 pM). Stability 
of TB diagnostic test is improved at acidic conditions in presence of salt and urea in the typical 
concentration range of human urine, which may due to the replacement of mAb with phage 
particles. This result demonstrates that phage particles replacing antibodies in the diagnostic test 
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This thesis contains 5 chapters that describe the development of a platform for detecting 
biological molecules based on employing highly modified bacteriophage as replacements for 
antibodies. The first chapter provides a framework for understanding the relevance of the work 
described in subsequent chapters and includes a brief introduction to diagnostic tests, a more 
focused discussion of the use of antibodies in immunological tests and some drawbacks and 
alternatives to antibodies as molecular components employed in diagnostics. A particular focus of 
the thesis is the development of diagnostics for resource limited environments and a discussion of 
the particular challenges and requirements for point-of-care diagnostics in the developing work is 
presented. The governing idea behind all of the experiments described in the thesis is that 
bacteriophages have all of the desired qualities of detecting molecules for point-of-care diagnostics. 
A description of the filamentous bacteriophages, the use of filamentous bacteriophages to select 
binding molecules through phage display, and the use of bacteriophages in diagnostics is presented. 
The second chapter describes the development of an alternative scaffold based on a small protein 
Sso7d from the thermophilic organism Sulfolobus solfataricus for binding molecule evolution, the 
construction of a phage displayed library of Sso7d variants and characterization of selected Sso7d 
variants that bind a diverse set of target proteins. The third chapter describes the use of the Sso7d 
phage library to select binding molecules that recognize a protein marker of active tuberculosis 
infection, Mycobacterium tuberculosis ornithine transcarbamylase (Mtb OTC), and the 
development of a diagnostic test employing phages and antibodies. The fourth chapter describes 
the development of a diagnostic test that employs predominantly modified phages for the detection 
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of Mtb OTC. The final chapter describes the production of a monoclonal antibody for the Mtb 
OTC protein. 
1.1 Diagnostics  
Diagnosis, the critical first step in the treatment of disease, often relies on the detection of 
specific biochemical markers. Approximately 7 billion medical tests are performed annually in the 
US to diagnose as well as monitor the progression of diseases and treatments. Medical diagnostics 
are often characterized by the type of molecules or cells they interrogate or the specific 
technologies employed in making measurements. General chemical tests measure the 
compositions of bodily fluids (general protein levels in urine or Ca2+ levels in blood). Cytology 
tests monitor the types and properties of cells in a sample, most commonly blood tests count and 
size red and white blood cells, biopsies evaluate cellular morphology to detect cancerous cells. 
Microbiological screens are employed to detect disease causing bacteria and fungi by growing 
cultures from isolated sampled tissues. The most specific and sensitive biological tests measure 
the levels of individual proteins or nucleic acids that are indicative of particular disease states. 
Nucleic acid tests are extremely sensitive and specific due to amplification through polymerase 
chain reaction (PCR), and are used to detect infections, genetic markers of disease, and measure 
levels of viruses like human immunodeficiency virus (HIV). Nucleic acid tests generally provide 
information about the genetic background but not the specific biochemical state of an individual. 
Tests that measure the levels or functions of specific proteins are the most direct measurements of 
biochemical functioning of a patient. Proteins levels are typically measured in 
immunohistochemical assays.   
Although new instruments and tests that rely on multiple different physical principles are 
constantly appearing, antibody-antigen interactions, the underlying biological recognition events
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used in many of these systems, have not changed greatly in the past 40 years. Typically, antibodies 
are generated using whole animal systems and produced in mammalian cell cultures. The process 
of generating antibodies is time consuming, expensive, and in the end gives only limited amounts 
of material. Additional steps are necessary if further genetic modifications and optimizations are 
desired. Beyond these difficulties, the physical properties of whole antibodies are not ideal as the 
components of diagnostics. Antibodies are not physically stable; they have limited process ability 
in diagnostics manufacture and need to be stored at low temperatures. Even then, antibody-based 
reagents have limited shelf lives. These drawbacks are critical in the developing world where 
diagnostic laboratories and even basic infrastructure are lacking. 
1.2 Antibody-based affinity diagnostic tests  
1.2.1 Antibodies introduction 
Antibodies, also called immunoglobulins, are antigen binding proteins that are secreted by B-
cells. The basic structure of an antibody molecule is a “Y” shape, including two identical heavy 
(H) chains and two identical light (L) chains, which are connected by disulfide bonds (Figure 1-
1). Both constant (CH and CL) and variable regions (VH and VL) exist in the heavy and light chains. 
The variable regions play a critical role in the binding of an antibody to an antigen, and the constant 
regions function as the supporting structure for the molecule. A comparison of the amino acid 
sequences of the VL and VH domains reveals that sequence variability is concentrated in three 
regions, named hypervariable regions, forming an antigen binding site. The hypervariable regions 
are also known as complementarity determining regions (CDRs) because the antigen binding site 
is complementary to the structure of an epitope which is the immunologically active region of an 
antigen. The remainder of the VH and VL regions exhibits far less variability than the CDRs and is 
termed relatively constant regions. These relatively constant regions form the β pleated sheet 
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structure of the VH and VL regions, and the six CDRs are located on the loops connecting the β 
strands. Although most antibodies are composed of two heavy and two light chains, both of which 
contribute to the antigen-binding sites, a heavy-chain antibody lacking light chains naturally exists 
in camelid 1 and shark 2, in which the antigen-binding site is formed by a single domain. The CDR3 
region of the heavy-chain camelid antibodies, compared with the CDR3 region of the conventional 
VH domain, possesses the capacity to form extended loops that can fit into cavities on antigens.  
The immunoglobulins can be classified into five major classes or isotypes: IgA, IgD, IgE, IgG, 
and IgM based on the differences among the heavy chain constant regions. IgD, IgE, and IgG 
antibodies function as monomers, while IgA functions as a dimer and IgM functions as a pentamer. 
IgG is the most abundant antibody in human serum and the most common tool for immunology 
research. Antibodies can be further classified as polyclonal antibodies (pAb) and monoclonal 
antibodies (mAb). pAb can recognize multiple epitopes since it is a pool of multiple mAbs. 
Monoclonal antibodies are specific to a single epitope and are widely used in immunology assay 
applications. 
Antibodies secreted from plasma cells continuously circulate in blood, recognizing or 
neutralizing antigens. The interaction between an antibody and an antigen is highly specific. The 
high specificity of antibodies led to the development of a variety of immunologic assays, including 
enzyme-linked immunosorbent assays (ELISA) and Western blots. These assays have been used 
to detect the presence of either antibody or antigen, which is important in disease diagnosis, 
mammal immune system response or other medical interests. mAbs have become the dominant 
form of new major biological pharmaceutics with multibillion dollars of annual sales. Since the 
first therapeutic mAb was commercialized in 1986, forty-seven mAb drugs have been approved in 
the US or Europe for the treatment of various diseases3, uch as Trastuzumab and Bevacizumab 
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for cancer therapy4, Rituximab for autoimmune disease treatment5, Alemtuzumab for transplant 
rejection prevention6. 
1.2.2 Antibody-based diagnostic tests  
Antibody-based diagnostic tests are usually designed based on the tight and specific interaction 
of the antibody and the biomarker to diagnose diseases. The most commonly used platform is an 
enzyme-linked immunosorbent assay (ELISA). Diagnostic tests usually employ some kind of 
complex body fluid, such as sputum, urine, or blood; the specific biomarker needs to be selected 
from the other components of the sample. Sandwich ELISA, which uses a pair of antibodies 
binding to different epitopes of the same biomarker, is the most commonly utilized platform. In a 
sandwich ELISA, an immobilized antibody captures the biomarker from the sample matrix, and 
then a second antibody binds to the captured biomarker. To develop a colorimetric or fluorescent 
signal, a third antibody conjugated with an enzyme, such as alkaline phosphatase (AP) or 
horseradish peroxidase (HRP), binds to the Fc region of the second antibody. Sandwich ELISA 
tests are often used in a qualitative (yes or no) mode to determine if a biomarker is present.  
Sandwich ELISA tests can also be quantitative, if a standard curve is made, the ELISA signal can 
be converted into a measure of the amount of analyte present. 
Lateral flow assay (LFA) diagnostic tests are another very common design7. LFA tests are 
similar to the sandwich ELISAs in that a pair of antibodies with minimum binding competition to 
a same biomarker are needed. A detection antibody conjugated with an enzyme or colored 
particles7–10 binds the biomarker in a sample of some bodily fluid which is applied at one end of a 
paper strip. The sample and reagents flow through the paper strip towards the other end carrying 
the biomarker. A capture antibody is immobilized in a defined detection zone of the paper strip, 
captures the biomarker attached antibody/particle/enzyme conjugate as it flows across the 
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detection zone. The accumulation of the biomarker in the capture zone concentrates the enzyme-
based signal generator or the accumulation of the particles causes a colorimetric band to show up 
when the biomarker is present. Unlike sandwich ELISA, LFAs only make qualitative diagnoses. 
The best-known lateral flow sensor is common pregnancy test7. Pregnancy tests detect the 
hormone human chorionic gonadotropin (hcg) produced during pregnancy in urine. Pregnancy test 
is a model for the desired performance of a point-of-care diagnostic test. The test can be perform d 
without laboratory facilities and produces an easily readable colorimetric results within 10-20 min. 
The current generation of LFA test has high sensitivity and specificity due to integrating thin-layer 
chromatography, the identification of biomarker-specific antibodies and by labeling sensitive 
signaling component to LFA.11 
Dipstick assays are based on the immunoblotting principle.12,13 In dipstick assay, a paper or a 
membrane is usually used as an immobilization platform. However, it is different from LFA, not 
relying on lateral fluid flow through a membrane. In dipstick assay, a paper strip coated with a 
capture antibody is serial dipped into a multiple solution. Initially a blocking solution, then the 
diagnostic sample solution, then a solution containing a detection antibody conjugated with an 
enzyme or particles, a finally a substrate solution if needed. Multiple washes between each step of 
dipping are also needed. A blot will show the presence of biomarkers. The dipstick assay process 
is simple and easy, suitable for point-of-care diagnosis in resource poor countries.  
In addition to the above three antibody-based tests, many other combinations of antibodies and 
physical and chemical mechanisms of signal generation are applied as high sensitivity and 
specificity diagnostics tests. However, majority of those designs need laboratory facilities which 
are inaccessible in resource-limited areas.   
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1.2.3 Problems and challenges for the antibody-based diagnostic tests applying for resource-
limited areas 
A test for diagnosing diseases in resource-limited areas should be sensitive, specific, as well 
as affordable and suitable for point-of-care application. Point-of-care usage means the tests do not 
need laboratory facilities, ideally are laboratory-free, and do not need specially trained staff for the 
assay. Further, the physical components should be conveniently delivered to and stored in areas 
without refrigeration or places without reliable power. The ELISA, LFA and dipstick tests 
mentioned before are all excellent candidate diagnostic test designs for resource-limited areas 
applications that suffer due to some issues caused by antibodies. Antibodies usually are not stable 
to elevated temperature and need to be carefully stored at cold conditions, which constrains the 
delivery and storage of the test reagents in resource-limited areas. Additionally, the generation, 
production and purification processes of antibodies significantly extend the time for the assay 
development and increase the cost of the diagnostic tests. In undeveloped areas, like some areas in 
Africa, even $1 per assay is too expensive. Cheaper is better and ideal situation is no cost. To solve 
these potential problems of antibodies, for a resource-limit areas diagnostic test development, other 
binding components need to be used, such as M13 phage particles.            
1.3 Phage-based diagnostic tests 
1.3.1 Filamentous bacteriophage introduction 
The filamentous bacteriophages are a family of rod shaped viruses packaging a single-stranded 
DNA (ssDNA) genome capable of infecting a wide variety of gram-negative bacteria, including 
Escherichia coli, Xanthomonas, Thermus, Pseudomonas, Salmonella and Vibrio 14. The most well 
characterized filamentous phages are the Ff class. The Ff phages are so named because they enter 
the host bacterial cell via the tip of the F conjugative pilus on the surface of male (F+) E. coli cells. 
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The Ff phage family contains the phages M13, fl and fd, all of which show 98% homologous DNA 
sequences and nearly identical protein sequences.15–17  
Filamentous phages are made and secreted from the host E. coli cells without cell killing or 
lysis. Therefore, the phages can accumulate to titers as high as 1011 to 12 particles per mL along 
with propagation of the host E. coli cells. The length of engineered Ff phage depends on the length 
of packaged DNA. So far, the only known constraints on the length of packaged DNA results from 
shearing of assembled phages. After infection, the viral single-stranded DNA is converted to a 
double-stranded intermediate form during the replication process. Both the ssDNA and the dsDNA 
forms can be isolated alternatively from phage particles or infected cells. Ff phages found an early 
biotechnological application as a cloning vehicle to obtain ssDNA for sequencing. The Ff phage 
is tolerant to insertions of foreign genes into non-essential regions. A gene of interest can 
additionally be fused with one of the coat protein genes. The resulting phage particles display the 
encoded protein on the particle surface and containing the genes sequence packaged within the 
particles, providing a direct link between genotype and phenotype. The process of infection by 
phage, can be used to conveniently transfer genetic information between bacterial stains. The 
tolerance of foreign genes insertions, the direct linkage of phage phenotype and genotype, the 
possibility of manipulating both ssDNA and dsDNA, and the easy genome transfer between 
bacterial strains combine to make Ff phage, primarily M13, a convenient and versatile molecular 
biology tool.   
1.3.1.1 Structure of the phage 
The wild type Ff phages are approximately 6.5nm in diameter and 800 to 900nm in length.18 
Five coat proteins, p3, p6, p7, p8, and p9, form a somewhat flexible cylinder encasing a single-
stranded, covalently closed DNA phage genome of 6400 nucleotide (Figure 1-2). Approximately 
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2700 copies of the major coat protein, p8, form the cylindrical body of each wildtype M13 
bacteriophage. The other coat proteins are termed minor coat proteins since only five copies of 
each are present in each phage particle. These minor proteins comprise the two ends of a phage 
particle: p3 and p6 form one end, while p7 and p9 form the other. The particle weight of wildtype 
M13 phage is approximately 16.3MD and 87% of the mass is contributed by coat proteins. 18  
The cylinder formed by major coat protein p8 compromises the largest component of the phage 
structure. The length of the cylinder depends on length of genome packaged in the particle. For 
wildtype M13 phage, approximately 2700 copies of p8 form the cylinder. Microphages can be 
constructed by packaging a 221 nucleotide single-stranded circle of DNA which contain only 95 
copies of p8.19 A p8 monomer is a 50-residue protein and forms α-helix structure except in the N-
terminal 5 residues. p8 proteins are arranged in an overlapping format with a symmetry defined as 
a 5-fold rotation axis and a 2-fold screw axis with a pitch of about 32Å.20 The p8 monomer α-
helices are uniformly parallel to the particle axis and tilted by an inclination angle in the range of 
13° and 20° with respect to the filament axis as determined by polarized Raman spectroscopy.21  
1.3.1.2 Phage genome and gene expressed proteins 
Complete sequences of the genomes of Ff phage, F1, M13 and Fd are known and they encode 
nearly identical protein sequences.15–17 Each genome encodes 11 proteins involved in the phage 
life cycle (Table 1-1). The 11 protein-coding genes are grouped in the genome according to their 
function.18 g2, g5, and g10 encode proteins required for the replication of phage genome. g3, g6, 
g7, g8, and g9 encode the coat proteins. g1, g11, and g4 encode proteins involved in the membrane-
associated assembly process. The phage genome is tightly packed containing overlapping genes 
except a short sequence, intergenic region, between g2 and g4. The intergenic region does not 
encode for any protein but contains the phage origins of DNA replication and a packaging signal 
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(PS). The intergenic region is tolerant to foreign gene insertion such as antibiotic resistance gene22. 
The phage origin of replication binds the phage DNA replication protein which initiates the phage 
genome replication process. The PS is a 78-nucleotide hairpin with function in phage assembly 
initiation.  
All five phage coat proteins are synthesized in cytoplasm and inserted into cytoplasmic 
membrane of the host E. coli cell. The major protein, p8, is synthesized as a fusion with a 23 amino 
acid N-terminal signal peptide directing the insertion of the protein into cytoplasmic membrane. 
The signal peptide is removed by a specific peptidase after insertion, resulting in a 50-residue 
mature p8 with its N-terminal 20 amino acids located in the periplasm and its C-terminal 10 amino 
acids exposed in the cytoplasm.23–25 The minor protein p3 is also inserted in the membrane with 
the help of an N-terminal signal peptide that is removed after insertion, resulting in the C-terminal 
residues of mature p3 in the cytoplasm and the N-terminal residues exposed to the periplasm.26 
The other minor coat proteins, p6, p7, and p9, are synthesized without a signal peptide, and the 
mechanism of their insertion into the membrane is unknown.  
The proteins involved in the assembly process, p1, p11, and p4, all reside in the cytoplasmic 
or outer membrane. Protein p4 is synthesized with a 21-residue N-terminal signal peptide and is 
suggested to be translocated to the periplasm via the Sec secretion system of the host cell.27,28 p1 
and p11, are inserted into the cytoplasmic membrane by the SecA pathway.28 Multiple copies of 
these assembly proteins cooperate to form a channel through the cytoplasmic and outer membrane 
allowing the phage particles to be released from the host cell without lysis.18 The Ff phage infection 
is not fatal and allows the host cells to produce phage particles and continue to grow. Proteins p2, 
p5, and p10 function in the replication process, and these 3 proteins all reside in the cytoplasm 
where the replication process occurs. 
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1.3.1.3 Life cycle of the phage 
The Ff bacteriophage life cycle can be generalized n three major steps: infection, replication, 
and assembly. 
1.3.1.3.1 Infection  
Phage infection is a complex process requiring interaction of the particle with the F conjugative 
pilus of the host cell and the bacterial cytoplasmic membrane proteins TolQ, TolR, and TolA. 
Although the complete details of process are not fully understood, the main phage protein 
responsible for infection is p3. p3 contains three domains connected by flexible glycine rich linkers 
named N1, N2, and CT.29 The N1 and N2 domains play an important role in the phage infection 
process, and removal of these 2 domains renders phage particles noninfective.30,31 Th  N2 domain 
binds to the F conjugative pilus at the initiation of infection.29,32 The phage genome is then 
translocated into the cytoplasm, facilitated by the N1 domain of p3 binding to domain 3 of the 
TolA (TolA-D3) protein.33 The process by which the coat proteins are disassembled in the 
cytoplasmic membrane and the exact function for other coat proteins in the infection process are 
unclear.     
1.3.1.3.2 Replication 
Once the single-stranded phage genome denoted as (+) strand enters the cytoplasm, the 
complementary (-) strand is synthesized by bacterial enzymes, and the parental replicative double 
stranded form (RF) DNA is produced. The (-) strand serves as a template for transcription, and the 
synthesized messenger RNAs are translated into the 11 phage proteins. The (+) strand is replicated 
with the help of phage protein p2 and bacterial host enzymes. Early in infection newly synthesized 
(+) strands are convertd to additional RF DNA with newly synthesized complementary (-) strands. 
Through this process, the pool of RF DNA is produced, leading to a buildup of the phage proteins. 
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However, the accumulation of viral ssDNA and phage proteins does not increase infinitely. Two 
regulation proteins, p5 and p10 serve to balance the production of viral ssDNA and the phage 
proteins. p5 regulates the synthesis of RF DNA by binding to the newly synthesized (+) strands 
(p5-DNA complex), preventing conversion of (+) strands to RF DNA. At a critical concentration 
of p5, RF DNA synthesis is terminated. p10 is also involved in the replication of phage DNA and 
appears to be an inhibitor of p2, although its exact role is unclear.34 
1.3.1.3.3 Assembly 
Phage particle assembly involves the passage of the p5-DNA complex across the bacterial 
membranes with the combination removal of p5v and addition of p8 molecules. During assembly, 
p5 is removed from the p5-DNA complex, and the coat proteins are assembled around the ssDNA. 
The assembly process contains three steps: initiation, elongation, and termination. Assembly is 
initiated by the DNA packaging signal that interacts with p1, p7, p9, and the first few copies of 
p8.35,36 The p7/p9 end is the first part of the particle to be extruded from the assembly site, which 
is a channel between the cytoplasmic and the outer membranes formed by p1, p11, and p4. The 
elongation process continues by replacing p5 with additional copies of p8 around the ssDNA. 
Assembly is terminated near the end of the ssDNA by the addition of p3 and p6 to the end of the 
particle. Release of the phage particles from the host cell membrane requires the CT domain of 
p3.37 If the CT domain of p3 is absent, the phage particle already protruding from the membrane 
will continue packaging multiple ssDNAs and will not be released from the cell membrane.  
1.3.2 Phage display 
Phage display is a biotechnology that primarily utilizes filamentous phage.38 Phage display 
involves the generation of large combinatorial libraries of peptide, protein or antibody sequences 
displayed on the surface of a phage particles that encode the sequence of the displayed protein. 
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Phage display is not only widely used to select binding molecules like antibody fragments, peptides 
and other scaffolds but also has been used to map interacting surfaces or discover protease 
recognition sites.  
Foreign proteins are presented on the surface by fusing the foreign protein gene to the gene for 
one of the phage coat proteins. The resulting phage particles display the encoded protein on the 
particle surface, providing a direct link between phenotype and genotype. The coat proteins p3 and 
p8 are most commonly used in phage display although display on each of the five coat proteins 
has been demonstrated.39–42 Proteins displayed on the N-terminus of p3 or p8 stretch out from the 
phage particle surface, enabling access to binding partners. Large fusion proteins on p3 appear to 
be packaged into phage particles reasonably well, which is a distinct advantage for p3 display over 
display from the rest of the coat proteins. However, p3 display of large proteins may lower or even 
eliminate the infectivity of the phage particles.18 In order to overcome this limitation, monovalent 
p3 display is usually applied by utilizing phagemid/helper phage system which will be described 
later. A Maximum of five copies of a displayed molecule per phage particle can be possible 
employing p3 display.  
While p3 display enables from one to five copies of a fusion protein to be displayed per particle, 
p8 has the potential to enable approximately 2700 fusion proteins to be displayed on the surface 
of each M13 phage particle. When the displayed peptide is smaller than ~8 amino acids, all copies 
of p8 can display the peptide of interest.43 Larger peptides and proteins (>10 residues) are generally 
inefficiently displayed on multiple copies of p8. In particles where large fusions are made with 
p8, >99% of the p8 proteins tend to be wild type.44–46 The main reason behind the p8 display size 
limitations is the assembly process of the phage. One thought is that when a large protein is 
displayed on p8, the assembled phage particle cannot pass through the 7nm exit hole formed by 
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p1, p11, and p4.47,48 Additionally, protein size may interfere with the ability of p8 to pack properly 
for stable particle formation. Recently, efforts have been devoted to increase the level of large 
protein display on p8. The display level of human growth hormone on p8 was increased 100-fold 
by selecting the optimized p8 from 3 randomly mutated p8 libraries that span the N-terminal 30 
amino acids of the wild type p8.49   
Two types of vectors are frequently used for phage display: phage and phagemid (Figure 1-3). 
Phage vectors typically employ a single copy of each coat protein and the nucleotide sequence of 
peptide to be displayed is inserted as a fusion to the coat protein. All copies of the coat protein 
used for display will be a fusion instead of wild type (Figure 1-3). This type of display is termed 
polyvalent display and is useful for selecting low affinity binders from a library. Phage particles 
produced in phage vectors are homogeneous both phenotypically and genotypically. However, the 
phage vectors are difficult to manipulate at the DNA level due to the large genome size and the 
overlapping DNA sequences of the 11 phage proteins. 
Monovalent phage display (Figure 1-3), in which on average only one copy of the coat protein 
displays the inserted peptide or protein, is accomplished using a combination of a helper phage 
and a second type of vector, a phagemid. Phagemids are relatively small vectors that contain the 
phage origin of replication, the packaging signal (PS) and, usually, one of the phage coat proteins. 
A phagemid vector is easier to manipulate at the DNA level compared to the full phage genome 
due to its smaller size and simple DNA structure. A phagemid vector needs another “helper” vector, 
a helper phage, to supply the other proteins needed for phage production (Figure 1-3). A helper 
phage contains a defective PS and therefore when a phagemid is present, phage particles prefer to 
package the phagemid genes with an optimal PS, but a small portion (usually 1-10%) of the phage 
particles still packages the helper phage genome. Fusion p3 expressed in the phagemid and 
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wildtype p3 from the helper phage are randomly assembled into phage particles. As a result, phage 
particles produced in a phagemid/helper phage system are both phenotypically and genotypically 
heterogeneous. This type of display has two advantages: (i) since wild type p3 is always present 
on the particles, the infectivity will not be greatly affected; (ii) this type of display is better suited 
for selection of high affinity binding molecules because avidity effects are eliminated.38  
For phagemid display, a helper phage is essential for the replication and assembly of the phage 
particles. However, a helper phage can cause contamination because some of the phage particles 
still package the genome of the helper phage. Depending on a variety of factors related to the 
particular system, the number of phage particles packaging the helper phage genome can 
sometimes equal, or exceed, the number of those packaging the phagemid.50 The Bradbury lab 
developed M13-based helper plasmids to eliminate the need for a helper phage.50 These helper 
plasmids contain all the genes of the supplementary phage proteins but do not contain the 
packaging signal or phage origin of replication, meaning no ssDNA is produced. The helper 
plasmids perform the same function as a helper phage without their ssDNA being packaged. As a 
result, genetically pure phagemid particles are produced. Furthermore, by using helper plasmids 
with different versions of p3: full-length p3, truncated p3, or deleted p3, phage particles produced 
by a phagemid vector are either monovalent or polyvalent (Figure 1-4).  
1.3.3 Antibody-based scaffolds for phage display  
In molecular biology and medicine, antibodies have traditionally been used as specific binding 
molecules for diagnostics and therapeutics. Antibodies are large multidomain proteins, on the 
order of 150 kDa, which require dimerization and formation of key disulfide bonds to function 
properly. The antigen-binding elements of antibodies, complementarity determining regions 
(CDRs), consist of closely-packed loop structures connecting the β-strands in the immunoglobulin 
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fold. The majority of the amino acid diversity in antibodies is focused in the CDRs of the heavy 
and light chain variable domains. The remaining “scaffold” of the immunoglobulin domain 
contains only minor variability and serves to present the CDRs in a three dimensional context. In 
contrast to the 150 kDa size of antibodies, p3, the largest M13 coat protein, is only 42 kDa. 
Displaying the intact antibody on phage surface is challenging.  
Two recombinant forms of antibodies with reduced size are commonly employed in phage 
display: the fragment antigen binding51,52 (Fab) and single-chain fragment variable53,54 (scFv) 
scaffolds (Figure 1-5). Both Fabs and scFvs represent considerable reductions in size relative to 
an entire antibody, 50 kDa and 25 kDa, respectively. The Fab format consists of two chains which 
are expressed independently, one chain as fusion to an M13 coat protein. The other chain must be 
assembled with the phage after expression. The scFv is an antibody fragment with a covalent 
linkage connecting the variable regions of the heavy chain and light chain. scFvs can be express d 
as a fusion to one of the phage coat proteins from a single gene. Another interesting antibody 
fragment with an even smaller size is a single domain antibody55 (sdAb) or nanobody with a 
molecular weight in the 12~15kDa range. sdAbs contain only one domain, an either variable 
domain or engineered constant domain of a typical antibody. One of the most widely used sdAb is 
VHH, which contains one heavy-chain variable domain, engineered from heavy-chain antibodies 
found in camelids.56 VHH nanobodies have high affinity and specificity as well as stability, small 
size, high solubility and benefit of multiple re-formatting opportunities. For phage display, an 
sdAb gene is attached to one coat protein and expressed as a fusion.  
Those antibody fragments with reduced size are demonstrated to have not only same antigen-
binding properties as the intact antibodies, but also advantages in tumor penetration, drug delivery, 
plasma clearance, conjugation with imaging molecules as well as for phage display than the intact 
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antibody.57,58 Antibody fragments commonly service as library scaffolds for the evolution of 
binding molecules via phage display56,59,60. However, the physical properties of antibody 
fragments are less than ideal for many applications, especially in point-of-care diagnostic 
applications with elevated temperature, extremely pH conditions, high ionic strength occurring. 
Additionally, Fabs and scFvs show a tendency toward aggregation, causing problem in many 
applications.61  A perfect scaffold that could be universally applied to all therapeutic and diagnostic 
applications does not exist. To overcome the potential limitations of the antibody fragments, a 
continuing search for non-antibody-based protein scaffolds that can be evolved into specific 
binding molecules is ongoing.   
1.3.4 Non-antibody-based scaffolds for phage display  
Although antibody-based scaffolds are the dominant class of engineered proteins for molecular 
recognition in therapeutic and diagnostic applications, antibody fragments have some limitations, 
such as large size, instability at high temperature or in harsh chemical conditions, dependence on 
intrachain disulfide bonds. Non-antibody-based scaffolds or alternative scaffolds are of increasing 
interest because in vitro selection techniques enable tight binding variants of alternative proteins 
to be selected that possess the improved properties over antibodies, such as small size, high 
stability, absence of cysteines, high yield bacterial expression and compatibility with multiple 
detection methods as well as maintain the high affinity and specificity. Multiple proteins have been 
identified to have the potential to be used as alternative scaffolds by phage display. Some 
alternative scaffolds, such as fibronectin domains (monobodies) 62, mimic the loops structure of 
antibodies to form the antigen-binding sites. Other scaffolds, such as Designed ankyrin repeat 
proteins (DARPins) 63, small helical proteins (affibodies) 64, form a flat binding surface instead of 
mimicking the CDR structure of antibodies.  
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Fibronectin is a large protein essential in the formation of the extracellular matrix and cell-cell 
interactions and consists of many repeats of three types (I, II and III) domains. Fibronectin type II 
(FN3) is a small (94 amino acid residues, 10kDa) monomeric protein domain consisting seven β-
sheets and has been used as a phage library scaffold by randomizing the loops connecting β sheets 
analogous to the CDR 1, 2, 3 structure in VH of antibodies62.  FN3 scaffold has been used for 
evolution of binding molecules against multiple protein targets in pM binding affinity.62,65,66              
DARPins are tightly packed repeat proteins.67,68 Each repeat module contains 33 amino acid 
residues and forms a structural unit consisting of a β-turn followed by two antiparallel α-helices. 
DARPins usually consist of four to six repeat modules and form a groove-like binding surface.69 
The molecular mass is about 14kDa for four-repeat DARPins. In each repeat module, six surface-
exposed residues are potentially engaged in the interactions with antigens and randomized to 
construct a library. The rest residues are critical for maintaining the stable structure, and therefore 
kept conserved. DARPins have been display on phage via the cotranslational signal recognition 
particle (SPR) dependent system70 instead of the traditional posttranslational Sec system. This is 
because DARPins fold very fast in cytoplasm. And the twin arginine transport (TAT) system71, a 
third transport system in E. coli which has been successfully used for super-folded green 
fluorescent protein (sfGFP) display on p340, was not functional for  display of DARPins on p372. 
From DARPins phage library, binding molecules have been selected against a wide targets, such 
as HER2 73, caspase-2 74, MAP kinase 75, aminoglycoside phosphotransferase 76, with affinity in 
the range of nM to pM.          
Affibodies were originally engineered from a three-helix-bundle B domain in the 
immunoglobulin-binding region of staphylococcus aureus protein A. The B-domain was 
engineered, denoted as the Z-domain, by mutating a single site in helix 2 to improve chemical 
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stability, quench the binding affinity to Fab but retain the binding affinity to Fc region.77 The 
affibody is composed with a 58-amino acid residue protein domain with small size (6kDa). The 
affibody has been used as a scaffold for the construction of combinatorial phage libraries and 
specific binding molecules have been identified from the phage libraries against a wide range of 
targets, such as insulin-like growth factor-1 receptor (IGF-IR)78, HER279, Alzheimer amyloid β 
peptides80, EGFR81, IgA82, TNF-α83, with affinity in the M to pM.      
1.3.5 Phage as a component of diagnostic tests 
Although antibodies are the dominantly utilized binding molecules in diagnostics, in recent 
years, phage particles have started o replace antibodies and be applied to the diagnosis of 
disease84,85. Utilizing phage particles to establish a diagnostic test has significant advantages over 
antibodies: First, the growth and isolation of phage particles is much faster, easier and cheaper 
than the production of antibodies; Second, phages have increased stability towards pH, elevated 
temperatures and organic solvents compared to antibodies; Third, phage displaying binding 
molecules can be conveniently identified from phage-displayed libraries and panning process in 
vitro, the development period is much shorter compared to the generation of antibodies. Multiple 
antibody-based diagnostic test platforms have the potential to replacing antibodies with phage 
particles. Sandwich ELISA has been demonstrated to utilizing phage particles as binding 
components, such as a Staphylococcal enterotoxin B (SEB)86 detection, a prostate cancer 
diagnostic test87.    
After the tight and specific binding molecules are selected from the phage library, the binding 
molecules are usually sequenced, cloned into a protein expression plasmid and purified from the 
cell culture. Although small binding molecules have advantages in biomedical imaging in vivo due 
to the easiness of conjugation with fluorophores and better tumor penetration properties, removal 
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of binding molecules from the phage platform can sometimes dramatically decrease the binding 
affinity, which is a universal problem for any kind of display technology. To overcome this issue, 
applying the whole phage particles to construct a diagnostic test in vitro not only reduces the risk 
of losing binding affinity to minimum, but also significantly reduces the cost and shortens the 
development time by avoiding the additional cloning and purification steps. Additionally, phage 
particles can service as an affinity matrix to extend the binding molecules from the immobilization 
surface and allow the binding molecules access to the biomarkers in solution. For example, in an 
ELISA assay milk powder or bovine serum albumin (BSA) are applied to passivate the surface 
and prevent non-specific binding of analyte. The size of BSA or albumin in milk powder is larger 
than some peptides or small protein binding molecules and can block the access of the binding 
molecules to the analyte in solution. By applying the whole phage particles in assay, phage 
particles function as a long linker to maintain the functional binding structures as well as allow the 
access to the analyte.     
Multiple protein scaffolds have been displayed on phage surface with diverse structures, 
molecular sizes, physical and chemical properties. Construction of phage display libraries and 
identification of binding molecules against protein targets, small molecules, cell surface receptors 
via panning have become an important technology. The binding molecules selected through phage 
display technology compare favorably with the high binding affinity and specificity of traditional 
antibodies. Phage particles have the potential to replace antibodies to establish diagnostics and 
based on different diagnostic applications, appropriate phage library scaffolds could be selected 





1.4 Tuberculosis  
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis 
(Mtb), which typically affects the lungs (pulmonary TB), but can affect other organs or tissues as 
well (extrapulmonary TB). TB is spread from person to person via droplets forced into the air by 
pulmonary patients coughing.88 
The treatment of TB usually involves a six-month regimen of antibiotics. A combination of 
anti-TB medicines developed in 1940s and 1950s, such as isoniazid and rifampin, greatly reduces 
the mortality rate of TB patients. In 2009, the cure rate reached 87% at the global level, which is 
the highest cure rate in TB treatment history.89 Although efficient treatment has existed for decades, 
TB was declared a global public health emergency by the World Health Organization (WHO) in 
1993 when an estimated 7 ~ 8 million new TB cases and 1.3~1.6 million TB-related deaths were 
reported.89 In 2010, still an estimated 8.5~9.2 million cases, among which an estimated 290,000 
cases of multidrug-resistance TB (MDR-TB) existed, and 1.2~1.5 million deaths were reported.89 
In 2014, TB surpassing human immunodeficiency virus (HIV) became the leading cause of death 
from infectious disease worldwide for the first time and caused 1.2 million deaths.88 Outbreaks of 
multiple drug resistance (MDR-TB) and TB-HIV-co-infection in recent years have contributed 
greatly to the high mortality rate and have made diagnosis and treatment of TB more complex.  
A great challenge to reducing the morbidity and mortality of TB is the lack of sensitive and 
reliable diagnostics that are affordable and suitable for point-of-care application. The primary TB 
diagnostic method at point-of-care in the under developed areas is sputum smear microscopy 
developed 100 years ago. Sputum smear microscopy lacks sensitivity especially for cases where 
co-infected with HIV is involved. In routine clinical practice, the sensitivity of sputum smear 
microscopy varies between 35% and 80% in HIV-negative patients, but drops to as low as 20% 
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among HIV-infected patients.90 A much more sensitive TB diagnostic is culture incubation, 
regarded as gold standard for TB diagnosis by the WHO. Culture incubation can diagnose TB as 
well as screen for drug resistant TB. However, culture incubation requires a laboratory, highly 
trained staff and an efficient transport system to ensure viable sputum samples arrive in a timely 
manner. Additionally, the culture process takes weeks to obtain results. In high TB burden areas, 
such as South-East Asia, Western Pacific Regions, and most of Africa, laboratory facilities are 
usually inaccessible, which constrains the application of culture diagnostics at point-of-care in 
resource-limited areas. Since 2010, the WHO started to provide a nucleic acid amplification based 
diagnostic Xpert MTB/RIF which can diagnose TB and rifampin resistance within 2 h with high 
sensitivity and specificity.91 However, in one study 12 false-positive rifampin resistance cases out 
of 22 tested TB cases were identified using the Xpert MTB/RIF test.92 And Xpert MTB/RIF was 
found to identify DNA from nonviable, degraded bacilli from patients recovered from previous 
TB infections also leading to false positive results.93 Additionally the cost of Xpert/MTB/RIF is 
often prohibitively high considering the cost of the equipment ($17,000) and each test cartridge 
($9.98).  
None of the above described diagnostic methods satisfies the “affordable, effective and suitable 
for point-of-care” criteria for an ideal TB diagnostic test. And the above described methods are 
constrained in diagnosing extrapulmonary TB, which requires that samples of the suspected organ 
or tissue be collected by biopsy. Biopsy needs highly trained staff and laboratory facilities. 
Additionally even for pulmonary TB, since the main method of diagnosis involves identifying 
presence of Mtb in sputum samples, sputum samples sometimes are challenging to obtain for 
example in children and are risky for health workers when appropriate protections are unavailable. 
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Because of the above issues, development of novel affordable, effective and suitable for point-of-
care (ideally laboratory-free) TB diagnostics is highly encouraged by the WHO.  
Pathogen-derived biomarkers or host response based diagnostics triggered wide interest for TB 
diagnosis. For pathogen-derived biomarkers or host response based diagnostics, urine or blood 
serves as diagnostic samples. Urine and blood are much safer to handle compared with sputum. 
Additionally, those diagnostics have the potential to diagnose pulmonary TB as well as extra 
pulmonary TB using one sample assay. However, the pathogen biology and interaction betwee
host and pathogen are only partially understood causing frustration in attempts to exploit the host 
response in antibody detection diagnostic assays.94,95 In 2011, the WHO recommended against 
using host response based tests for diagnosing pulmonary and extrapulmonary TB.89 A major effort 
has been devoted to identifying pathogen-related biomarkers which could be translated into a 
specific and sensitive diagnostic tests.   
Keeping in mind the criteria of an ideal TB diagnostic, non-invasive samples like urine 
triggered the greatest interest because urine is more convenient to obtain, safer to handle and has 
a simpler composition than other body fluids, such as sputum and blood. The process of obtaining 
urine is painless to patients and special training for health workers is not needed, all of which make 
urine based diagnostics very suitable for applications in local health centers of under-developed 
countries.  
Multiple groups have been devoted to finding pathogen-related biomarkers in urine of TB 
patients. Among all the identified biomarker candidates, lipoarabinomannan (LAM), which is a 
structurally important component of the outer cell wall of Mtb, is the most frequently targeted 
molecule. Several clinical studies have been applied to screen people with suspected TB by using 
anti-LAM ELISA tests. Tessema reported a sensitivity of 74.0% and specificity of 86.9% in 
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Ethiopia.96 Boehme reported a sensitivity of 80.3% and specificity of 99% in Tanzania.97 However, 
another 4 studies show consistently poor overall test performance with sensitivities ranging from 
13% to 51%.98–101 These results suggest little consistency for the detection of urine LAM in 
patients with suspected TB. Determine™ TB-LAM (Alere Inc., USA), a commercial lateral flow 
based strip TB diagnostic by detecting LAM, was identified to have good sensitivity in HIV-co-
infected patients with the most advanced immunodeficiency102 and therefore is promising to be 
used as an “add-on” test instead of replacing the primary test sputum smear microscopy. Although 
there is progress for applying LAM detection in TB diagnosis, the LAM-based diagnostic is still 
far from ideal. Identification and validation of other pathogen-derived markers in urine is a top 
priority in the development of new TB diagnostics.           
The Campos-Neto laboratory found that Mtb ornithine transcarbamylase (Mtb OTC, Rv1656) 
in urine could work as a possible molecular marker of active pulmonary TB.103 They first 
discovered Mtb OTC in urine of patients with pulmonary TB by mass spectrometric survey. 
Western blot analysis showed this protein was also present in Mtb crude cell extracts as well as in 
the culture supernatant, which suggests the protein in urine probably originates from Mtb and is 
not degraded by the host metabolism. The protein was detected by the IgG antibodies from active 
TB patients but not by those from uninfected healthy subjects. These results suggest Mtb OTC as 
a promising marker for active TB diagnosis. The Mtb OTC was chosen as the diagnostic target of 
our diagnostic tests. To our knowledge, no available diagnostic tests have been developed towards 























Figure 1-4. The phage particle genotypes and phenotypes when using the standard phagemid and 






Figure 1-5. Structure of a full length antibody molecule and two shortened versions of antibody 





Table 1-1 Proteins involved in the f1 phage life cycle and their function as well as molecular 
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Protein Function No. of amino acids∆ Protein MW ∆ 
p2 DNA replication 410 46,137 
p10 DNA replication 111 12,672 
p5 Binding ssDNA 87 9,682 
p8 Major coat protein 50* 5,235* 
p3 Minor coat protein 406* 42,522* 
p6 Minor coat protein 112 12,342 
p7 Minor coat protein 33 3,599 
p9 Minor coat protein 32 3,650 
p1 Assembly 348 39,502 
p4 Assembly 405* 43,476* 
p11 Assembly 108 12,424 
∆The initiating methionine is included in the proteins. 
*The number of amino acids and the molecular weight for p3, p8 and p4 are for the 
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Phage display selection of tight specific binding variants from a hyperthermostable Sso7d 
scaffold protein library* 
   
 
 
Antibodies, the quintessential biological recognition molecules, are not ideal for many 
applications because of their large size, complex modifications, and thermal and chemical 
instability. Identifying alternative scaffolds that can be evolved into tight, specific binding 
molecules with improved physical properties is of increasing interest, particularly for biomedical 
applications in resource-limited environments. Hyperthermophilic organisms, such as Sulfolobus 
solfataricus, are an attractive source of highly stable proteins as starting points for alternative 
molecular recognition scaffolds. We describe the first application of phage display to identify 
binding proteins based on the Sulfolobus solfataricus protein Sso7d scaffold. Sso7d is a small 
(approximately 7 kDa, 63 amino acids), cysteine free DNA-binding protein with a melting 
temperature of nearly 100 °C. Tight binding Sso7d variants were selected for a diverse set of 
protein targets from a 1010 member library, demonstrating the versatility of the scaffold. These 
Sso7d variants are able to discriminate among closely-related human, bovine, and rabbit serum 
albumins. Equilibrium dissociation constants in the nanomolar to low micromolar range were 
measured via competitive ELISA. Importantly, the Sso7d variants continue to bind their targets in 
the absence of the phage context. Furthermore, phage-displayed Sso7d variants retain their binding 
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Sso7d scaffold will be a complementary addition to the range of non-antibody scaffold proteins 
that can be utilized in phage display. Variants of hyperthermostable binding proteins have potential 
applications in diagnostics and therapeutics for environments with extreme conditions of storage 
and deployment. 
2.1 Introduction 
Tight, specific binding molecules are important components of medical diagnostics and 
therapeutics. Phage display developed as an in vitro method to select and evolve binding molecules 
through the creation and screening of large libraries of peptides or proteins displayed on the surface 
of phage particles. Binding molecules are selected by panning a library against an immobilized 
target and retaining those particles that bind 1,2. The bound particles are eluted, amplified through 
propagation in bacteria, and rescreened. Several rounds of binding and amplification allow the 
selection of tight binding variants from billions of starting sequences. Beyond phage display, the 
nanoscale size, simple life cycles, and speed and ease with which they can be prepared, 
manipulated, and characterized render phages attractive and versatile systems for myriad 
biotechnological applications.  
The filamentous bacteriophage M13 is most commonly employed for phage display, and M13 
systems are at the forefront of research in nanomaterials 3–7 nd nanomedicine 8–11. Fusion proteins 
have been displayed on every one of the five M13 coat proteins 12–15, and platforms utilizing 
combinations of several, but not all, coat proteins have been developed 14,16–18. Modified phage 
displaying simultaneous fusions to two coat proteins have been used build nanowires 16, con truct 
components of batteries 19, produce components for biosensors 5, and act as tissue engineering 




elements and produce large quantities of decorated phage particles is central to the 
biotechnological uses of M13.  
Generating highly decorated phage is challenging because the small size and close packing of 
phage coat proteins as well as the phage assembly process all place constraints on the display of 
fusion proteins 22. M13 particles consist of a single-stranded DNA genome encased in 
approximately 2700 copies of a major coat protein (p8) and five copies each of four minor coat 
proteins: p3 and p6 on one end and p7 and p9 on the other. Protein fusions are most commonly 
displayed on the minor coat protein p3, the largest coat protein whose sequence of 406 amino acids 
forms three globular domains. p3 is employed for monovalent display of large proteins for 
selection, but attempts to display proteins on all 5 copies of p3 often lead to decreased phage yields. 
p7, p8 and p9 are all 50 or fewer amino acids in length, and packing interactions leave limited 
space for displayed fusions. p6 is rarely used for phage display. Particle production involves 
passing the assembling phage through a membrane-spanning pore complex that further limits the 
size of fusions on the phage surface 23,24. Many of the advanced applications of phage particles as 
components of materials, as imaging probes and therapeutic delivery vehicles would benefit from 
the ability to display multiple fusions in a controlled and high valent manner. One approach to 
overcome the bias against the display of large proteins on phage is to develop functional proteins 
of reduced size.  
In molecular biology and medicine, antibodies have traditionally been used as specific binding 
molecules for diagnostics and therapeutics. Antibodies are large multidomain proteins, on the 
order of 150 kDa, which require dimerization and formation of key disulfide bonds to function 
properly. The antigen-binding elements of antibodies, complementarity determining regions 
(CDRs), consist of closely-packed loop structures connecting the β-strands in the immunoglobulin 
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fold. The majority of the amino acid diversity in antibodies is focused in the CDRs of the heavy 
and light chain variable domains. The remaining “scaffold” of the immunoglobulin domain 
contains only minor variability and serves to present the CDRs in a three dimensional context. In 
contrast to the 150 kDa size of antibodies, p3, the largest M13 coat protein, is only 42 kDa. Two 
recombinant forms of antibodies with reduced size are commonly employed in phage display: the 
fragment antigen binding (Fab) and single-chain fragment variable (scFv) scaffolds. Both Fabs 
and scFvs represent considerable reductions in size relative to an entire antibody, 50 kDa and 25 
kDa, respectively. The Fab format consists of two chains which are expressed independently, with 
one as fusion to an M13 coat protein. The other chain must assemble with the phage after 
expression. scFvs, while expressed as a fusion to one of the phage coat proteins from a single gene, 
exhibit a tendency to dimerize, which can complicate selections 25,26. 
Although antibody fragments remain the most common framework for the evolution of binding 
molecules via phage display, the physical properties of antibodies are less than ideal for many 
applications and other protein scaffolds are continuously being developed 27,28. Additionally, a 
recent review of commercial antibodies has suggested that many antibody reagents are of highly 
variable quality and often poorly characterized.29 Some non-antibody-based alternative scaffolds 
such as fibronectin domains (monobodies) 30 and single immunoglobulin domains (nanobodies) 31 
mimic the CDRs of antibodies. These scaffolds are on the order of 10 kDa, less than half the size 
of a scFv. Other scaffolds such as Ankyrin repeat proteins (DARpins) 32 and small helical proteins 
(affibodies) 33 display diversity in structural contexts that do not mimic the CDRs of antibodies. 
While larger than fibronectin domains and monobodies, 12-18 kDa DARpins and affibodies are 




utilized as reagents for protein purification and detection and have potential as diagnostic imaging 
and therapeutic agents 34,35.  
Three properties are particularly important when considering a protein as a possible scaffold. 
Small size, on the order of 60 amino acids or fewer, is desirable for production and for ease of 
modification. Protein stability, preferably in the absence of disulfide bonds, improves formation 
and maintenance of the desired structure in diverse environments. The tolerance of a protein 
toward mutation at several simultaneous positions is related to protein stability, and stability of the 
“parent” protein correlates with the ability to select functional variants via directed evolution 36. 
For greatest utility, binding variants should retain their function in the absence of the phage context. 
Facile expression in bacterial culture is desirable for the production of large quantities of a selected
binding protein in an industrial setting. Further, scaffold domains of fewer than 60 amino acids 
have the potential to be synthesized chemically, rather than biologically, which expands the 
possibilities of diversification through chemical modification, including employment of non-
natural amino acids 37.  
The continued identification and development of small, stable binding scaffolds is important 
because increasing the diversity of three-dimensional architectures available as library templates 
should allow the selection of binding molecules with improved physical properties for diverse 
targets of different shapes. Because the space of target molecular structures is vast, scaffolds of 
different shapes are needed to identify appropriate binding interfaces. Some architectures will 
naturally be more compatible than others. The increased stability and decreased size of alternative 
scaffolds comes at the potential price of generality of interaction. The use of multiple scaffolds 
with different folds in a single selection experiment has the potential to allow the direct selection 
of specific binders for multiple epitopes on a single target 38.  
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A natural, but largely unexplored, source for small, highly stable protein scaffolds are the 
genomes of hyperthermophilic organisms. Because of the severe conditions under which these 
organisms live, their proteins have evolved to withstand greatly elevated temperatures and often 
extremes of pH and salt. Many proteins or protein domains from these organisms satisfy all of the 
desirable criteria for an alternative binding scaffold. High thermostability is especially attractive 
for biomedical applications in resource-limited environments.   
Sso7d is a small 7 kDa, 63 amino acid, cysteine free, DNA-binding protein with a melting 
temperature of nearly 100 °C from Sulfolobus solfataricus. Sso7d is representative of an abundant 
class of 6-8 kDa, putative histone-like molecules isolated from thermophilic Sulfolobus species 39. 
Sso7d and the closely related Sac7d from Sulfolobus acidocaldarius possess a nearly identical 
three-dimensional structure and share 85% sequence identity and have been studied extensively as 
model thermophilic and DNA binding proteins 40,41. Their three-dimensional structures have been 
characterized both in solution and in the solid state and consist of an incomplete five-s rand d β-
barrel closed off by a C-terminal α-helix (Figure 2-1) 42,43. This fold, labeled the OB-fold, is found 
in diverse binding molecules that recognize oligonucleotides, oligosaccharides, proteins, and metal 
ions 44.  
With an eye toward expanding the toolkit for high level, multivalent display of evolved binding 
molecules on phage and a particular interest in thermostable scaffolds for molecular recognition, 
we demonstrate the efficient display of Sso7d on M13 as a p3 fusion and describe the generation 
of a large phage display library of Sso7d variants from which tight binding proteins for a variety 
of targets were isolated. Sso7d and Sac7d have been used as scaffolds in yeast and ribosome 
display libraries 45–48, but to our knowledge, this report is the first demonstration of successful 
phage display of Sso7d.  
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2.2 Results and Discussion 
2.2.1 Sso7d phagemid constructs 
The gene for an Sso7d variant selected via yeast display to bind streptavidin (Sso7d-strep) was 
assembled by sequential thermodynamically balanced inside out synthesis (seqTBIO) 47,49,50 and 
inserted into phagemid vectors designed to evaluate superfolder green fluorescent protein (sfGFP) 
display on M13 phage. The vectors (generous gifts from Andrew Bradbury) contain cassettes 
encoding TAT, SRP or Sec leader peptides that direct a sfGFP-p3 fusion protein to the inner 
membrane via alternative secretion systems 51. DNA encoding a hexahistidine tag is located 
between the genes for the phage displayed protein and full length p3 as part of a single reading 
frame. The Sso7d gene was cloned into each of the phagemids in place of the sfGFP gene to 
produce TAT-Sso7d-strep, SRP-Sso7d-strep, and Sec-Sso7d-strep. In the conversion of the 
vectors from sfGFP to Sso7d-strep displaying phagemids, a suppressible stop codon between the 
hexahistidine tag and the gene for p3 was removed. Successful cloning was monitored by loss of 
fluorescence in transformed cells and verified by sequencing.  
2.2.2 Translocation signal dependent display of Sso7d  
Successful insertion of the Sso7d-p3 fusion protein into the E. coli inner membrane is critical 
for effective phage display, as all phage coat proteins contain transmembrane segments prior to 
particle assembly 52. Protein transport in E. coli can accommodate either folded or unfolded 
proteins and be accomplished either co- or post-translationally. The two phage proteins most 
commonly used for phage display, p3 and p8, have peptide leader sequences that direct 
translocation across the cytoplasmic membrane post-translationally while the coat proteins are 
unfolded via the Sec pathway 53. The pelB leader sequence in Np3-Sec triggers translocation via 
the Sec pathway and is commonly used for phage display vectors. The Signal Recognition Particle 
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pathway (SRP) is similar to the Sec pathway in that proteins are translocated in an unfolded state, 
but the pathway operates co-translationally 54. SRP leader sequences have been used to improve 
the phage display of ankyrin-based scaffolds for which the Sec leader was ineffective 55. Proteins 
that are stably folded or that require the reducing environment of the cytoplasm for proper folding 
can be transported in a native form via the Twin Arginine Transport (TAT) pathway. Phage display 
of functional, fluorescent sfGFP was achieved using a TAT leader peptide 51,56.  
Sso7d is small, highly stable and disulfide-free. The most efficient system for translocation of 
this protein in E. coli is not obvious a priori. Bacteria containing the Sec-Sso7d-strep, SRP-Sso7d-
strep or TAT-Sso7d-strep phagemid were infected with M13KO7 helper phage. Similar yields of 
particles (on the order of 1012/mL of bacterial culture) were achieved for each of the three 
phagemids. ELISA with an anti-hexahistidine tag antibody was utilized to evaluate the extent of 
incorporation of the Sso7d-strep-p3 fusion protein into phages as a function of leader peptide, 
independent of the streptavidin-binding function of the Sso7d-strep variant. Immobilization of 2-
3 x 1010 Sec-Sso7d-strep and SRP-Sso7d-strep phages gave rise to strong ELISA signals, greater 
than 20-fold over background, suggesting successful incorporation of the Sso7d-p3 fusion (Figure 
2-2). ELISA signals for both M13KO7 (no Sso7d variant displayed) and TAT-Sso7d-strep were 
not above that observed for blocked wells. Preliminary experiments suggested that the phage 
displayed context of Sso7d-strep may have compromised its ability to bind streptavidin. The same 
phages did not show any signal over background when evaluated with a streptavidin-HRP 
conjugate in ELISAs. 
2.2.3 Library design and construction 
Based on the levels of display facilitated by the three leader peptides, Sec-Sso7d-strep wa  
selected as the template for the construction of a library of Sso7d variants. Analysis of the binding 
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faces of OB-fold proteins and the previously-reported yeast display Sso7d and ribosome display 
Sac7d libraries suggested 9 positions for randomization 39,45,47,48. The 9 amino acids are located on 
the exposed surfaces of the 3-stranded β-sheet that makes up the DNA binding interface of Sso7d 
(Figure 2-1b). The library was constructed using the degenerate codon NNC which encodes 15 of 
20 amino acids (excluding Met, Lys, Glu, Gln, and Trp) and does not introduce any stop codons. 
The theoretical size of the library is 169 = 6.9 x 1010 DNA sequences encoding 159  = 3.9 x 1010 
protein sequences.  
In an effort to reduce background of unmodified template in the library preparation, a staring 
template was constructed in which 7 of 10 codons between positions 22 and 31 in the Sso7d 
scaffold were replaced by the rare arginine codons AGA or AGG (Sec-Sso7d-rArg, Table 2-1). 
The rare Arg codons are expected to reduce the translation of the starting template and place a 
metabolic burden on cells 57. For ease of identification of library members, a unique XbaI 
restriction site was also introduced into Sec-Sso7d-rArg. Both the XbaI restriction site and the rare 
Arg codons are removed by the mutagenic primer during library construction. The Sec-Sso7d-rArg 
library template displays poorly on phage based on anti-His tag ELISA (Figure 2-2). 1013 purified 
Sec-Sso7d-rArg phage particles gave rise to an ELISA signal that was approximately 2.5-fold over 
background. For comparison, strong ELISA signals approximately 30-fold over background were 
observed for 1010 phage particles prepared from Sec-Sso7d-strep without the rare arginine codons. 
Two of seven arginine mutations, V22R and I29R, place positively charged residues into the 
hydrophobic core of Sso7d, possibly lowering protein stability or inducing misfolding. Increased 
metabolic burden, reduced stability and lower levels of correctly folded protein may all contribute 




The phage displayed Sso7d library was constructed using Kunkel mutagenesis with a single 
mutagenic primer. Transformation of the reaction into SS320 cells resulted in 1.3 x 1011 unique 
transformants. The mutation efficiency was evaluated by analyzing XbaI digests of PCR products 
from 95 isolated colonies. The amplified fragment from a library member is not cut by XbaI, while 
the unmodified rare Arg template is digested. 12 of 95 colonies were identified as library members. 
DNA sequencing confirmed that each of those variants were unique library members. Considering 
mutagenic efficiency, the library contained 1.6 x 1010 individual variants. To further evaluate the 
diversity of the library, a total of 56 randomly selected library members were sequenced. The 
diversity of the library was evaluated using the statistical methodology of Rodi, Soares and 
Makowski, which describes a measure of library diversity that is a based on approximating peptide 
probabilities in the library using observed residue frequencies and comparing the observed 
distribution to a theoretical ideal where each peptide sequence is encoded by an equal number of 
nucleotide sequences.58,59 This method has the advantage of calculating a measure of diversity that 
can be compared across libraries produced using different encoding strategies. The diversity in the 
first six (of nine total) randomized positions exhibit an essentially unbiased distribution of amino 
acids. Some bias toward the amino acids that were present in the starting template was apparent in 
the last three diversified positions. Even with this bias, our library (de= 0.096) includes 
approximately 1.5x the functional diversity of the commercially available 7 and 12 amino acid 
peptide phage display libraries (de=0.079 and de=0.043 for New England BioLabs PhD 7 and 12 
libraries) 59. 
The yeast display Sso7d and ribosome display Sac7d libraries largely under sampled their 
theoretical diversity. The ribosome display libraries were constructed using NNS codons at either 
10 or 14 positions. The theoretical sizes of these libraries were 1015 or 1021 DNA sequences of 
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which approximately 1012 independent variants were obtained 45,48. The yeast display libraries 
varied 10 positions using NNN codons (DNA sequence diversity of approximately 1018) and 
contained approximately 107 surface displayed sequences 47. Effective directed evolution 
experiments generally strike a balance between theoretical diversity and adequate coverage of that 
diversity 60. Variants with high affinity for the intended targets were identified using both the yeast 
and ribosome display systems. In this phage display study, a reduced codon set was employed to 
allow more thorough coverage of the theoretical diversity of the encoded library. 
2.2.4 Library selection 
In order to examine the ability to identify high affinity Sso7d binding variants via phage 
display, the library was evaluated against four target proteins: bovine serum albumin (BSA, 66 
kDa), rabbit serum albumin, (RSA, 66 kDa), neutravidin (60 kDa), and green fluorescent protein 
(GFP, 27 kDa). BSA and RSA were included to assess the ability of Sso7d variants to distinguish 
between closely related proteins. Related experiments have been described for the small helical 
protein, albumin binding domain 61. Neutravidin was included as a close structural, but 
sequentially unrelated, analog of streptavidin to compare against the Sso7d-strep binding sequence 
isolated by yeast display.  
For each of the four protein targets, three or four rounds of panning against passively adsorbed 
target were performed (Table 2-2). The enhancement of the population of phages with affinity for 
the target protein with increasing rounds of selection was monitored by evaluating the retention of 
amplified phages. The ratio of phages from the amplified pool binding to target coated versus 
uncoated wells is a measure of functional selection and is expected to increase as panning 
progresses. In the last round of panning for BSA, neutravidin and GFP, the relative enhancement 
of binding to target coated versus uncoated wells was approximately 105-fold (Table 2-2). A very 
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modest enhancement of 12-fold was observed for the RSA panning experiments, suggesting poor 
selection. 
After the final round of panning, isolated clones were grown overnight in 96-well microplates. 
The supernatants of these small cultures were assayed for target-specific binding via phage ELISA. 
Based on phage yields after large scale purification, we estimate that approximately 1010 phage 
particles were utilized in these ELISAs. Supernatants from 23 of 23 clones grown after the fourth 
round of selection against BSA gave rise to high ELISA signals (greater than 10-fold over 
background). DNA sequencing of 10 of these clones revealed 3 different protein sequences (Table 
2-1). Supernatants from 20 of 23 clones grown after 4 rounds of panning against neutravidin gave 
rise to high ELISA signals. DNA sequencing of 9 of these clones revealed largely similar 
sequences, identical at 7 of 9 amino acid positions. Supernatants from 18 of 24 clones grown after 
3 rounds of panning against GFP gave rise to high ELISA signals. DNA sequencing of 10 clones 
revealed 10 different protein sequences, with some consensus of amino acid types at each 
randomized position. Supernatants from 3 of 48 clones grown after 3 rounds of panning against 
RSA showed strong ELISA signals; all 3 isolated variants had the same protein sequence. 
2.2.5 Evaluation of selected serum albumin binding Sso7d variants: 
In complex environments, often in the presence of many related molecules, antibody 
recognition is highly specific. The Sso7d scaffold presents a smaller and more rigid binding 
interface than the CDRs of antibodies, which could decrease the ability of Sso7d-derived binding 
molecules to distinguish among closely related targets. The Sso7d variants identified from panning 
the phage library against both BSA and RSA were evaluated for binding to three serum albumin 
proteins: BSA, RSA, and human serum albumin (HSA). These three proteins have approximately 
75% sequence identity and greater than 86% sequence similarity. 
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The 10 clones characterized from the BSA binding variants encoded 3 protein sequences 
(Table 2-1). Two of the three protein sequences 2A4 and 2A6 describe 9 of 10 variants 
characterized and contain identical or very closely related amino acids at 7 of 9 varied positions. 
The remaining Sso7d variant 2A8 is distinct from the 2A4/2A6 clones, containing amino acids 
that differ in size or polarity at 5 of 9 varied positions. The sequences of the BSA binding clones 
are largely unrelated to the single isolated RSA binding sequence.  
ELISA experiments to evaluate the specificity of the selected albumin binding sequences for 
immobilized BSA, RSA and HSA targets were performed. Sso7d-RSA-13A8, Sso7d-BSA-2A4, 
Sso7d-BSA-2A6, and Sso7d-BSA-2A8 phages were purified, concentrated and 1010 particles for 
each variant were analyzed. None of the phage displaying Sso7d variants identified by panning 
against BSA or RSA showed any detectable binding to HSA (Figure 2-3). Sso7d-RSA-13A8 
showed greater than 12-fold specificity for RSA over BSA. Sso7d-BSA-2A8 showed an 
approximately 9-fold specificity for BSA over RSA. ELISA signals for Sso7d-BSA-2A4 and Sso7-
BSA-2A6 binding to RSA were identical to those observed for both HSA-immobilized and 
blocked wells, suggesting specificities of at least 60-fold for these two variants. Significantly, for 
all Sso7d variants specificity arises without any pre-selection step for undesired affinity (e.g. 
negative selections against the opposing serum albumin protein). Taken together these results 
suggest that the rigid Sso7d scaffold is capable of highly specific interactions with closely related 
proteins.  
2.2.6 Evaluation of selected neutravidin binding Sso7d variants: 
Neutravidin (the deglycosylated form of egg white avidin) is structurally and functionally 
similar to the bacterial protein streptavidin, although the primary sequences of these two proteins 
share only 47% similarity. Both proteins exist as tetramers of 8-stranded β-barrel folds and bind 
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biotin with femtomolar affinity.62,63 The Sso7d-variants that bind neutravidin identified by phage 
display show some similarity to the sequence of the streptavidin-binding Sso7d variant identified 
by yeast display (Table 2-1). In particular, the amino acids on the binding face of β-strand 5, Ser 
40, Ile 42 and Tyr 44, are identical in the neutravidin and streptavidin binders. The amino acids on 
the other two β-strands of the neutravidin binding Sso7d variants are quite different from the 
corresponding residues identified in the streptavidin binding sequence from the yeast library.  
DNA sequencing of 9 clones found by screening the Sso7d phage library against neutravidin 
revealed 6 different but closely related sequences, identical at 7 of 9 amino acid positions. The 
consensus sequence includes Phe 23, Asn 25, His 30, Arg 32, Ser 40, Ile 42, and Tyr 44. Within 
the set of neutravidin-binding Sso7d variants, the amino acids at positions 21 and 28 exhibited 
some diversity, with aromatic, polar, and long chain alkyl amino acids identified. Position 21, the 
first variable residue in β-strand 3, varied between His, Leu and Phe. Greater variation in side 
chain size and composition was observed at position 28, which is on the leading edge of β-strand 
4. Five different amino acids were selected in the nine sequenced clones.  
Phage ELISA provided a qualitative evaluation of the binding affinity and specificity of the 
streptavidin (Sec-Sso7d-strep) and neutravidin (Sso7d-neutravidin-2D6) binding variants (Figure 
2-4). Neither Sso7d variant binds to the opposing target. ELISA signals from the addition of 1010-
1012 Sso7d-neutravidin-2D6 phages to wells containing passively adsorbed streptavidin were not 
above background. Likewise, the ELISA signals from the addition of 1010-1012 Sso7d-strep phages 
to wells containing passively adsorbed neutravidin were not above background. In our hands, the 
Sso7d streptavidin binding variant identified by yeast display does not bind streptavidin efficiently 
when expressed in the context of phage. Although ELISA utilizing the anti-His tag antibody to 
evaluate display levels suggested high level display of the Sec-Sso7d-strep variant (Figure 2-2), 
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addition of 1012 Sec-Sso7d-strep phage particles to a streptavidin-coated well gave rise to ELISA 
signal of only approximately 5-fold over background. Based on quantification of phages purified 
and concentrated from larger culture volumes, we estimate that on the order of 1010 phage particles 
are added to each well when using small volume supernatants for ELISA to identify binders. 
Sso7d-strep would not have been identified from the phage library as a streptavidin binder, as the  
signal was not significantly different than that for addition of Sso7d-strep phages to a blocked well. 
In contrast, 1010 Sso7d-neutravidin-2D6 phage particles added to a neutravidin-coated well gave 
rise to an ELISA signal of 67-fold over background. Signal from the supernatant ELISA used to 
identify 2D6 as a binder resulted in an overflow signal, and ELISA signal from 109 purified phages 
still resulted in signal more than 10-fold over background. 
2.2.7 Evaluation of selected GFP binding Sso7d variants: 
GFP has a β-barrel fold structurally similar to neutravidin, but larger in size (11 versus 8 
strands). GFP is monomeric as opposed to the tetrameric organization of neutravidin. DNA 
sequencing of 10 clones identified as GFP binders by supernatant ELISA revealed 10 different 
protein sequences which exhibit strong consensus of amino acid types at 6 of 9 varied positions 
(Table 2-1). Position 21 contained small amino acids Ala and Ile. Position 23 showed a weak 
preference for hydrophobic residues Ile or Leu (5 of 10 clones). A strong consensus of amino acid 
size or type was not evident at position 25. Position 28 was either Asp or Asn in 8 of 10 clones. 
Position 30 favored polar residues His, Thr or Tyr (9 of 10 clones). Position 32 favored small 
amino acids Ala, Ser and Gly (9 of 10 clones). Positions 40 and 42 preferred small hydrophobic 





2.2.8 Estimation of binding affinity by competitive ELISA (on-phage) and ITC (off-phage) 
Purified phages were evaluated by ELISA to select a single clone for quantification of binding 
affinity. Phage particles displaying each of the sequenced Sso7d variants were evaluated in a series 
of phage ELISA experiments with decreasing concentrations of phage particles. The clone giving 
rise to the highest signal at lowest concentration was selected for further characterization. Sso7d-
BSA-2A8, Sso7d-neutravidin-2D6, and Sso7d-GFP-6B9 were identified as the best binders of the 
selected clones for their respective target proteins. Those three Sso7d variants, along with Sso7d-
RSA-13A8, were characterized further. 
Competitive ELISA was used to estimate the binding affinity (ΚD) for each of the selected 
clones (Figure 2-5). Conditions for the competitive ELISA were established by identifying the 
concentrations of both phage particle and immobilized target protein that resulted in 50% 
saturation of the ELISA signal. For the competitive ELISA, phage particles at a single pre-
determined concentration were pre-incubated with increasing concentrations of the target protein 
prior to performing ELISA against immobilized target 57. 
The equilibrium dissociation constants of Sso7d-BSA-2A8 and Sso7d-RSA-13A8 were 
measured in the low micromolar range (3.5 M and 2.1 M, respectively, Table 2-3). Both the 
GFP and neutravidin binding variants displayed low nanomolar dissociation constants (6.2 nM and 
36.1 nM, respectively, Table 2-3). The selection of tighter binding variants against GFP and 
neutravidin may be related to the similarity in folds between these proteins and a propensity of the 
slightly concave Sso7d binding face to recognize the convex surface of β-barrel folds.  
The ability of Sso7d-BSA-2A8 and Sso7d-GFP-6B9 to bind their targets in the absence of the 
phage context was evaluated by isothermal titration calorimetry (ITC) (Figure 2-6). For most 
applications, binding molecules identified by phage display must retain the ability to recognize 
56 
 
their target once produced and deployed independent of the phage framework. Not infrequently, a 
decrease in binding affinity accompanies removal of the binding molecule from the phage context. 
Binding affinities determined by ITC for purified Sso7d-BSA-2A8 and Sso7d-GFP-6B9 were 
comparable to the on-phage values (Table 2-3), suggesting that the mutations to the binding face 
of the Sso7d scaffold required for specific binding do not alter the structural context of the overall 
protein.  
2.2.9 Thermal stability of Sso7d variants on- and off-phage 
High thermostability with relatively small size is one of the most appealing properties of Sso7d 
as a scaffold for developing specific binding proteins. Both M13 bacteriophage and the Sso7d 
scaffold protein are known to maintain their structure and function after exposure to elevated 
temperatures. Antibodies require careful handling to maintain their binding ability, and even 
minimal exposure to heat can greatly diminish their binding affinity. In order to evaluate the 
thermal stability of the Sso7d-BSA-2A8, Sso7d-RSA-13A8, Sso7d-neutravidin-2D6, and Sso7d-
GFP-6B9 proteins, phage displaying each variant were exposed to temperatures between 50 °C 
and 90 °C for 30 minutes and assayed for retention of binding ability by phage ELISA. Aliquots 
of each phage sample were incubated on ice to serve as a control. Each of the Sso7d displaying 
phages maintained binding ability comparable to that of the control sample after exposure to 
temperatures of up to 70 °C for 30 minutes (Figure 2-7a). After 30 minutes at 80 °C, Sso7d-
neutravidin-2D6 and Sso7d-RSA-13A8 lost the ability to bind to their target proteins. Some 
binding ability was retained for Sso7d-BSA-2A8 and Sso7d-GFP-6B9, but the ELISA signal was 
only a fraction of that observed after exposure to lower temperatures, 38% and 24% respectively. 
After prolonged exposure (up to 8 hours) to temperatures of 60 °C, both Sso7d-BSA-2A8 and 
Sso7d-GFP-6B9 phages retained significant binding ability (Figure 2-7b). 
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The melting temperature of each of the Sso7d variants identified by phage display was 
measured by differential scanning calorimetry (DSC) in the absence of the phage context (Table 
2-4). Purified Sso7d variants maintained high melting temperatures similar to that of the parent 
protein and well above temperatures at which the structural stability of most antibodies would have 
been compromised. Compared to the 98 °C melting temperature reported for wild type Sso7d, each 
variant was slightly less stable, although the least thermostable variant, Sso7d-BSA-2A8 still had 
a melting temperature of nearly 83 °C 64,65. Wild type Sso7d is a model, two-state reversibly-
folding protein, but each of the phage-selected Sso7d variants showed irreversible denaturation as 
evidenced by greatly reduced DSC endotherms for serial heating and cooling cycles. Similar 
folding defects were observed for some of the Sso7d variants selected by yeast display 47. 
Sso7d-BSA-2A8 phage particles maintain their structural integrity as measured by the ability 
of the particles to infect receptive cells after challenges up to 80 °C for 30 minutes. The infectious 
titer of the particles did not decrease relative to the sample of phages held on ice after incubation 
at 50 °C, 60 °C, or 70 °C. Titer decreased by 10-fold after incubation at 80 °C. The infectious titer 
of Sso7d-BSA-2A8 phages incubated at 90 °C for 30 minutes was below 104 cfu/mL, the detection 
limit of the titer assay. 
2.3 Conclusions: 
Antibodies have seen increasing roles as therapeutics, as in vivo and in vitro diagnostics, and 
as tools for laboratory research. However, antibodies are not ideal molecules for many applications 
because of their large size, multi-domain structure, poor stability, and high cost and difficulty of 
production. The drawbacks of traditional antibody-based reagents can be insurmountable in 
environments in which basic infrastructure for storage and deployment are lacking. The evolving 
needs for antibodies in biomedicine have fueled the continuing development of new scaffolds for 
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molecular recognition that exhibit improved physical properties. The demands of new applications 
translate into a set of desired molecular attributes that an engineered binding molecule should 
possess: small size, absence of disulfide bonds and post-translational modifications, high chemical 
and thermal stability, and the ability to be engineered to high affinity and specificity towards a 
given target. The burgeoning application of highly decorated bacteriophage particles as a platform 
for diagnostics, therapeutics, and other biotechnological applications requires additional 
compatibility of the scaffold protein with the phage coat architecture and particle assembly 
process. A largely unexplored but fertile source of new scaffolds are the protein domains of 
hyperthermophilic organisms. 
We have described the optimization of phage display of the OB-fold protein Sso7d from 
Sulfolobus solfataricus. We produced a large Sso7d phage display library and employed it to 
isolate Sso7d variants that bind a variety of target proteins. On phage, the binding interactions have 
dissociation constants in the low nanomolar to low micromolar range. When the Sso7d derivatives 
were analyzed for binding in the absence of the phage particle, the KDs observed with increased 
approximately 4-8-fold, as is often seen with binding molecules identified by phage display. The 
Sso7d variants retain their affinity for their target proteins when phage solutions are heated to 60 
°C for extended periods of time. The melting temperatures for purified Sso7d derivatives isolated 
from the phage library are slightly lower than the native Sso7d sequence, but still very high. Taken 
together, our results suggest that the Sso7d scaffold will be a complementary addition to the range 
of non-antibody scaffold proteins that can be utilized in phage display.  
2.4 Materials and Methods 
All enzymes for cloning and mutagenesis were purchased from New England Biolabs 
(Ipswich, MA, USA). Unless otherwise noted, antibiotics were used at the following 
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concentrationsμ carbenicillin (carb) 50 g/mL, tetracycline (tet) 30 g/mL, chloramphenicol (cam) 
5 g/mL and kanamycin (kan) 50 g/mL (Sigma-Aldrich, St. Louis, MO, USA). All liquid cultures 
were shaken at 225 rpm unless otherwise noted. All wash steps in ELISA and library panning are 
300 L. In this manuscript, all solutions containing phosphate-buffered saline (PBS) are made as 
137 mM NaCl, 2.7 mM KCl, 12 M Na2HPO4 and 1.2 mM KH2PO4 at pH 7.4. All oligonucleotides 
were purchased from IDT (Coralville, IA, USA). All constructs were verified by sequencing 
(Proteomics and Metabolomics Facility, Colorado State University).  
2.4.1 Construction of Sso7d gene and Sso7d-displaying phage vectors 
The gene for the streptavidin-binding Sso7d variant (Sso7d-strep) identified by yeast display 
47 was synthesized by sequential thermodynamically balanced inside out PCR (seqTBIO) 50 using
Oligos 1-8 (Table S2-1, Appendix 1) which allowed the introduction of unique restriction sites for 
cloning and full control over codon usage. The Sso7d-strep gene product was verified by 
sequencing. 
The Sso7d-strep TBIO product was inserted into Np3-TAT 51 using XhoI and NheI to give 
TAT-Sso7d-strep. Oligos 10 and 11 were used to amplify the Sso7d-strep-p3 gene segment from 
TAT-Sso7d-strep and install 5’ XhoI and 3’ EcoRI sites for cloning into Np3-Sec to generate Sec-
Sso7d-strep. Oligos 12 and 11 were used to amplify the Sso7d-strep-p3 gene segment from TAT-
Sso7d-strep with 5’ BssHII and 3’ EcoRI sites to generate SRP-Sso7d-strep. The Sso7d-strep-p3 
region of each phagemid was verified by sequencing (Table S2-2, Appendix 2).  
2.4.2 Preparation of phage particles 
Briefly, NEB 5-alpha F’ E. coli (F´ proA+B+ lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) / fhuA2∆(argF-
lacZ)U169 phoA glnV44 Φ80Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17) harboring the 
Sso7d-containing phagemid were grown to an OD600 of 0.5 at 37 °C in 2YT tet/carb/3% glucose. 
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Glucose was added to suppress expression of the Sso7d-variant-p3 fusion protein, to minimize 
growth discrepancies that may arise from the expression of Sso7d variants, and to maximize 
expression of the F pilus for helper phage infection 66. M13KO7 helper phage (multiplicity of 
infection, MOI = 20) were added to cells harboring the phagemids. Infected cultures were 
incubated at 37 °C for 30 min. Cells were pelleted by centrifugation for 5 min at 5000 ×g at room 
temperature and resuspended in 2YT tet/carb/kan without glucose to allow expression of the 
Sso7d-p3 fusion protein. Phage production proceeded overnight at 30 °C. Phage supernatants were 
prepared by centrifugation at 17,000 ×g to pellet the cells. For large volume cultures, phage were 
precipitated by decanting the supernatant from the pelleted cells into 1/5th volume polyethylene 
glycol (PEG) 8000/2.5 M NaCl in water 2. The phage pellet was resuspended in 1/100th of the 
original culture volume PBS. Typical phage yields were on the order of 1013-1014 particles from 
100 mL of cell culture. Phage concentrations were determined spectrophotometrically using the 
following formula (Abs. 269 nm – Abs. 320 nm) x 6 x 1016 / plasmid size (bp) 67. For long-term 
storage, phage particles were frozen in 14% glycerol. 
2.4.3 Phage enzyme-linked immunosorbent assay (ELISA) 
Display of the Sso7d-strep variant was confirmed using phage ELISA. MaxiSorp® 96 ELISA 
plates (Nunc Inc., Rochester, NY, USA) were coated with approximately 1010 purified phages 
prepared from cells harboring either TAT-Sso7d-strep, SRP-Sso7d-strep, or Sec-Sso7d-strep 
phagemids at 4 °C overnight. After washing 3 times with PBS each well was blocked with blocking 
buffer (PBS with 4% milk powder) for 1 h at room temperature. Blocked wells were washed 6 
times with PBS-Tween (PBST, PBS with 0.05% (v/v) Tween 20). Functional Sso7d-strep display 
was assayed immunohistochemically by incubation with anti-6x-His antibody HIS.H8 (1:1000 
dilution) (Pierce, ThermoFisher Scientific, Waltham, MA, USA) 2 hours at room temperature. 
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After washing 6 times with PBST (300 L per wash), 100 L of rabbit anti-mouse IgG/horseradish 
peroxidase (HRP) conjugate (1:3000 dilution, Pierce) was added to the well and allowed to bind 
for 1 h. The wells were washed 6 times with PBST, then twice with PBS. Colorimetric assays were 
performed using 1-Step Ultra TMB ELISA Substrate (Pierce). The reaction was quenched by 
addition of 2 M sulfuric acid after 30 min incubation at room temperature. Absorbance at 450 nm 
was determined using a Biotek Synergy H1 microplate reader. 
2.4.4 Library construction via Kunkel mutagenesis 
The library template Sec-Sso7d-rArg was generated from Sec-Sso7d-strep using Kunkel 
mutagenesis with Oligo 13 and verified by sequencing.68 The Kunkel mutagenesis procedure was 
adapted from Sidhu and Weiss 2. Briefly, cultures of CJ236 E. coli (FΔ(HindIII)::cat (Tra+ Pil+ 
CamR)/ ung-1 relA1 dut-1 thi-1 spoT1 mcrA) harboring the phagemid to be mutated were grown 
to an OD600 of 0.5 and infected with M13KO7 at a MOI of 20. The infected culture was transferred 
into 2YT cam/carb/kan/0.25 g/mL uridine/3% glucose. Cultures were grown overnight at 30 °C. 
Phage particles were concentrated as described above. Single stranded uridine-enriched (ss dU) 
DNA was isolated using the QIAprep Spin M13 kit (Qiagen, Germantown, MD, USA). 
The library was generated using 100 g Sso7d-strep-rArg DNA and a 10-fold molar excess of 
5’ phosphorylated Oligo 14. Following PCR spin kit cleanup and elution in ultrapure water, the 
library DNA was electroporated into SS320 cells ((MC1061 F’, Lucigen) 
[F’proAB+lacIqlacZΔM15 Tn10 (tetr)] hsdR mcrB araD139 Δ(araABC-leu)7679 lacX74 
galUgalK rpsL thi), resulting in 1.3 x 1011 unique transformants. 
After transformation, cells were infected with M13KO7 as described above and transferred to 
1 L of 2YT media with 30 g/mL tet, 60 g/mL carb, and 10 g/mL kan and grown overnight at 
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30 °C. Phage particles were isolated by PEG precipitation. Aliquots of the library in PBS/14% 
glycerol were stored at -80 °C. 
To determine the efficiency of mutagenesis, 95 single colonies were analyzed by colony PCR 
and a restriction test. Single colonies were used as a template for PCR amplification using Oligo 
15 and Oligo 16. Crude PCR products were subjected to XbaI digestion and analyzed by agarose 
gel electrophoresis.  
2.4.5 Selection of binding variants  
Sso7d binding variants were selected by panning the phage library against immobilized protein 
in 96 well plates. Target proteins BSA (EMD Millipore, Danvers, MA, USA), neutravidin (Thermo 
Scientific), RSA (Sigma-Aldrich) were used as supplied and sfGFP was expressed and purified in-
house. A GFP variant including an N-terminal hexahistidine tag and a C-terminal sortase 
recognition sequence (LPETGG) was cloned into a modified pQE40 protein expression vector. 
pQE40 had been modified in the laboratory to include an additional copy of the LacIQ gene from 
pBbB1A-GFP (Addgene plasmid # 35340, a gift from Jay Keasling 69) and the phage origin of 
replication from M13KO7. Proteins were coated to MaxiSorp® 96 well ELISA plates (Nunc Inc.) 
in coating buffer (1 g protein in 0.1 M Na2CO3, 0.1 M NaHCO3, pH 9.6) at 4 °C overnight. After 
3 washes, each well was blocked and washed as described above for ELISA. In the first round of 
selection, 5 target coated wells were used. In subsequent rounds, 4 wells were employed. For the 
final round of selection against BSA and neutravidin 2 wells were used. Approximately 1013 library 
phages were mixed 1μ1 with blocking buffer and added to each well (50 L of phage amplified 
from the previous round plus 50 L blocking buffer). After 2 hours at room temperature, unbound 
phage particles were discarded, and the wells were washed. Wash stringencies increased in each 
round of selection. In the first round of selection, wells were washed 3 times with PBS. Additional 
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washes with PBST were added for subsequent rounds of panning. The second round of selection 
included 3 PBST washes followed by 2 PBS washes. The third round of panning included 6 PBST 
washes followed by 2 PBS washes. The fourth round of selection (if performed) included 10 PBST 
washes followed by 2 PBS washes. Bound phages were eluted with 100 L of 100 mM glycine 
HCl, pH 2.2 for 25 min at room temperature. Eluent from multiple wells was combined and 
neutralized using 1.5 M Tris, pH 8.8. Neutralized phages were titered (see below) to determine the 
output of each round of selection (10 L of the pooled eluent). Collected phages were propagated 
in 5 mL of NEB 5-alpha F’ cells. After 30 min of incubation without shaking followed by 30 min 
of incubation with shaking, the entire culture was added to 15 mL 2YT tet/carb with 3% glucose. 
When the OD600 of the 15 mL culture reached 0.5, M13KO7 were added (MOI=50). Infected cells 
were spun and resuspended in 100 mL of 2YT tet/carb/kan media without glucose, followed by 
overnight amplification at 30 °C. Phages isolated by PEG precipitation and concentrated 100-fold 
were used for the following round of selection. Amplified phages were exposed to a blocked well 
during rounds 3 and 4 of selection to evaluate non-target protein specific phage retention. 
2.4.6 Phage titration 
To determine the phage output from each round, a 10-fold dilution series of the eluted phages 
was used to infect NEB 5-alpha F’ cells grown to OD600 0.5 at 37 °C. Phage infection was allowed 
to proceed for 30 min at 37 °C. At least 3 10 L spots for each phage dilution were plated on LB 
agar plates and incubated at 37 °C overnight. The titer of phage was calculated from the dilution 
with the highest number of countable colonies. 
2.4.7 Binding analysis of individual clones 
Individual clones from the final round of selection were picked into 150 L of 2YT tet/carb 
with 3% glucose in a λ6 well plate incubated at 37 °C overnight. The following day, 5 L of each 
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overnight culture was transferred to 150 L of 2YT tet/carb with 3% glucose in a fresh 96 well 
plate and regrown to OD600 of 0.5 (generally about 2.5 hours). M13KO7 was added to each well 
at a MOI of 20. After incubation at 37 °C for 30 min, the cells were pelleted by centrifugation at 
5000 ×g at room temperature and resuspended in 2YT tet/carb/kan without glucose. The 96 well 
plate was incubated at 30 °C overnight. Cells were pelleted at 17,000 ×g, and the phage 
supernatants were used in an ELISA assay to characterize the binding affinity of the Sso7d 
variants. 
ELISA plates were prepared as described above for panning the library. 50 L of the phage 
supernatants were mixed 1:1 with blocking buffer and added to individual wells. After 2 hours at 
room temperature, wells were washed 6 times with PBST. Bound phage were detected using an 
HRP-conjugated anti-M13 antibody (100 L, 1μ5000 dilution in blocking buffer) (GE Healthcare, 
Wauwatosa, WI, USA). After 1 h at room temperature, wells were washed 6 times with PBST and 
twice with PBS and visualized as described above. Clones displaying ELISA signal against the 
target protein that was 3-fold or greater over background (blocked wells) were considered hits. 
Across all target proteins, only 2 hits identified for neutravidin did not exhibit signal at least 30-
fold over background. Generally, plasmid DNA was isolated from 10 clones that bound each target 
protein and sequenced. 
2.4.8 Competitive ELISA to determine binding affinity 
A titration curve examining ELISA signal at different dilutions of both immobilized targe 
protein and purified phage was generated to determine the conditions which led to 50% saturation 
of the ELISA signal. Once the concentration for immobilized target protein was determined, wells 
for competitive ELISA were prepared as described above for the phage supernatant ELISA (Table 
2-5). Phage particles were pre-equilibrated with concentrations of target protein across five orders 
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of magnitude in blocking buffer for 2 hours at room temperature. A sample of phage that was not 
pre-equilibrated with target served as a reference for the 100% phage bound absorbance. 100 L 
of equilibrated phage solution were added to each ELISA well and allowed to bind for 15 min. 
ELISA was performed and visualized as described above. Absorbances at 450 nm for each 
concentration of competitor were normalized to the absorbance for the phage sample with no 
competitor. Data were plotted as relative A450 versus concentration of competitor. Dissociation 
constants were determined by fitting the data using a 4-parameter logistic equation (Appendix 3). 
Measurements were performed in triplicate for each experiment. Plots shown in Figure 2-5 are 
representative of a single experiment. KDs reported in Table 2-3 represent the average of at least 
three independent experiments. 
2.4.9 Heat tolerance of Sso7d variants on phage 
The heat tolerance of Sso7d displaying phages was evaluated by ELISA. Phage stock solutions 
were incubated at temperatures between 50 and 90 °C for 30 min or at 60 °C between 1 and 8 
hours. Control samples were incubated on ice for the duration of each experiment. After exposure 
to elevated temperatures, all phage were kept at room temperature for 1 hour. Phage solutions were 
diluted 100- to 300-fold in blocking buffer prior to performing ELISA as described above. The 
concentration of target protein coated to each well ranged from 125-1000 ng, depending on the 
concentrations that resulted in good ELISA signal during binding analysis of individual clones. 
2.4.10 Preparation and purification of Sso7d variants off phage 
Oligos 17 and 18 (Table S2-1, Appendix 1) were used to amplify Sso7d variants for cloning 
into a pET23b (Novagen/EMD Millipore) protein expression vector using NdeI and HindIII 
restriction sites. pET23b-Sso7d variants were verified by sequencing. Vectors were transformed 
into BL21(DE3) pLysS cells (F-, ompT, hsdSB (rB-, mB-), dcm, gal, (DE3), pLysS, Cmr, Promega, 
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Madison, WI, USA) by electroporation. 1.2 L of LB cam 30/carb 50 were inoculated from an 
overnight culture and incubated at 37 °C. Protein expression was induced when the culture reached 
an OD600 of 0.5 by addition of IPTG to a final concentration of 0.5 mM. Cells were grown 
overnight at 30 °C. Cells were harvested by centrifugation and lysed by sonication (Qsonica, 
Newtown, CT, USA). Protein was purified from the clarified lysate by Ni-NTA affinity 
chromatography on a BioLogic LP FPLC (BioRad, Hercules, CA, USA). Eluted proteins were 
dialyzed against PBS and quantified by Micro BCA protein assay (Pierce). Typically, yields of 
each Sso7d variant were between 30 and 40 mg/L with purities greater than 90%. 
2.4.11 Isothermal titration calorimetry (ITC) 
ITC experiments were performed on a Nano ITC 2G model 5300 (TA Instruments, New Castle, 
DE, USA) at 25 °C in PBS. Both the target protein and Sso7d variant were buffer exchanged into 
PBS to ensure that both proteins were in identical environments. All samples were degassed under 
vacuum. The reference cell was washed 5 times and loaded with degassed water. The sample cell 
and syringe were rinsed 5 times with degassed PBS. The instrument was operated in overflow 
mode. The concentration of each Sso7d variant was 10 to 15 times higher than that of the target 
protein. After auto-equilibration of the ITC, 2 L of Sso7d variant was injected in the first 
injection, folowed by 30 8 L injections with a 5 min equilibration between each injection. The 
sample cell was mixed by stirring at 300 rpm. Data were collected at 1 second intervals using the 
ITCRun software (TA Instruments) and analyzed using the independent model in NanoAnalyze 
(TA Instruments). Signal from a background titration monitoring addition of buffer to the protein 





2.4.12 Differential scanning calorimetry (DSC) 
DSC experiments were performed on a Nano DSC model 6300 (TA Instruments). Sso7d 
variants were buffer exchanged into PBS and diluted to a final concentration of approximately 0.5 
mg/mL. All samples were degassed under vacuum. Both the reference cell and the sample cell 
were rinsed with degassed PBS 3 times. Degassed PBS was used for background buffer scans. 
Two scan cycles, each consisting of one heating and one cooling cycle from 5 °C to 110 °C (1 
°C/min) were performed for each Sso7d variant. Data were recorded in DSC Run software (TA 
Instruments) and analyzed using the two state scale model in NanoAnalyze (TA Instruments). Each 






Figure 2-1. Sequence and structure of Sso7d from Sulfolobus solfataricus. (a) Primary sequence 
of Sso7d. Secondary structures are indicated beneath the sequence. The 9 bold, underlined amino 
acids indicate the diversified positions in the library. The variant used for library construction 
included an E35L mutation (indicated by *) to abolish Sso7d ribonuclease activity. (b) Sso7d with 
secondary structural elements color coded to match the cartoon in part a. Side chains shown as 





Figure 2-2. Effect of secretory pathway on the phage display level of the Sso7d streptavidin 
binding variant. A450 readings from phage ELISAs using anti-hexahistidine tag antibody to detect 
display of the Sso7d-strep-6His-p3 protein fusion on phage particles are shown for each construct, 
which is identified above by the translocation pathway targeted. Approximately 1010 particles were 
immobilized in each well, except for Sec-Sso7d-rArg for which approximately 1013 particles were 


























Figure 2-3. Specificity of selected Sso7d variant-displaying phage for related serum albumin 
proteins. BSA, RSA or HSA were immobilized in wells for ELISA. Bound phage were detected 
using an anti-M13 antibody. In all instances, approximately 1010 particles were added to each 



























Figure 2-4. Specificity of Sso7d variant-displaying phage for neutravidin and streptavidin. 
Neutravidin and streptavidin were immobilized in wells for ELISA. Bound phage were detected 
using an anti-M13 antibody. Approximately 1012 or 1010 particles were added to each well. All 









































Figure 2-5. Normalized competitive ELISA data for selected Sso7d variants. Phages were 
preincubated with ten different concentrations of soluble target protein prior to incubation in wells 
containing the same target protein. Anti-M13 antibody was used to detect phages that were retained 


































Figure 2-6. Affinities of purified Sso7d variants determined by isothermal titration calorimetry. a) 
ITC titrations of Sso7d-BSA-2A8 into BSA. Upper panel contains raw heat signals; bottom panel 
shows the integrated heats and fit using single site binding model, KD = 15100 ± 2000 nM. b) ITC 
titrations of Sso7d-GFP-6B9 into sfGFP. Upper panel contains raw heat signals; bottom panel 

























































































Figure 2-7. Retention of binding affinity after exposure of Sso7d variant displaying phages to 
elevated temperatures. (a) ELISA was performed after 30 minute exposure to temperatures 
between 50 °C and 90 °C. ELISA signal for each phage variant is normalized to the average A450 
determined for the sample incubated at 0 °C. (b) ELISA was performed after exposure to 60 °C 
for times between 1 hour and 8 hours. Bound phage were detected using an anti-M13 antibody. In 
all instances, approximately 1010 particles were added to each well. All data are represented as the 





























































Wild type Sso7da KKVWRVGKMISFTYDEGGGKTGRGAV 
Sso7d streptavidin (isolated from yeast display) WIVARDGKWIDFSYDLGGGKSGIGYV 
Sso7d rare arginine template WSRRRRGKRRRFRYDLGGGKSGIGYV 
Target  
BSA (10 clones sequenced)  
      Sso7d-BSA-2A4 (6)b 
      Sso7d-BSA-2A6 (3) 




RSA (3 clones sequenced) 
     Sso7d-RSA-13A8 (3) 
 
WYVNRFGKNIHFLYDLGGGKSGHGYV 
Neutravidin (9 clones sequenced)  
     Sso7d-Neutravidin-2D6 (3) 
     Sso7d-Neutravidin-2D8 (1) 
     Sso7d-Neutravidin-2E1 (1) 
     Sso7d-Neutravidin-2E2 (2) 
     Sso7d-Neutravidin-2E6 (1) 







GFP (10 clones sequenced)  
     Sso7d-GFP-6A2 (1) 
     Sso7d-GFP-6A7 (1) 
     Sso7d-GFP-6A8 (1) 
     Sso7d-GFP-6A9 (1) 
     Sso7d-GFP-6B2 (1) 
     Sso7d-GFP-6B3 (1) 
     Sso7d-GFP-6B4 (1) 
     Sso7d-GFP-6B7 (1) 
     Sso7d-GFP-6B8 (1) 











a The glutamic acid residue at position 35 of Sso7d was found to contribute to the protein’s 
ribonuclease activity. The E35L variant lacks ribonuclease activity; both the yeast and phage 
libraries include Leu at position 35. 
b The number in parenthesis next to each clone denotes the frequency of occurrence of that 






















BSA 4 2 x 108 2 x 103 1 x 105 23/23 
RSA 3 5 x 104 4 x 103 12.5 3/48 
Neutravidin 4 7 x 108 2 x 103 3.5 x 105 22/23 
GFP 3 4 x 108 1 x 104 4 x 104 18/24 
Output and enhancement calculations are those for the final round of selection. Phage ELISA 
for individual clone analysis was performed after the final round of selection. 
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Table 2-3. Apparent equilibrium dissociation constants (KD) for selected Sso7d variants on- and 
off-phage. 
 
Sso7d Variant KD (on-phage) KD (off-phage) Ratio 
Sso7d-BSA-2A8 3500 ± 600 nM 15100 ± 2000 nM 4.3x 
Sso7d-RSA-13A8 2100 ± 900 nM ----- ----- 
Sso7d-neutravidin-2D6 6.2 ± 1.7 nM ----- ----- 
Sso7d-GFP-6B9 36.1 ± 0.8 nM 298 ± 48 nM 8.3x 
Data are presented as mean ± standard deviation (n = 3 for on-phage competitive 





Table 2-4. Thermostability of Sso7d variants. 
 
Variant Tm (°C) 
Sso7d-wt 98 
Sso7d-BSA-2A8 82.7, 82.6 
Sso7d-RSA-13A8 88.9, 87.4 
Sso7d-neutravidin-2D6 94.0, 93.8 
Sso7d-GFP-6B9 86.1, 87.1 
Analysis was performed for 2 samples of each Sso7d variant; 










Table 2-5 Conditions for competitive ELISA 
 
Target Protein and 
Sso7d Variant Pair 
Protein Coated 
to Each Well 
Dilution Factor of 
the Phage Stock 
Concentration Range of 
Competitor Protein 
BSA and 2A8 250 ng 160 2.6 x 10-10 M to 5 x 10-4 M 
RSA and 13A8 500 ng 103 2.2 x 10-10 M to 8.4 x 10-5 M 
Neutravidin and 2D6 31 ng 80 6.1 x 10-10 M to 1 x 10-5 M 
GFP and 6B9 125 ng 88 6.4 x 10-9 M to 1.3 x 10-4 M 
Target proteins were diluted 2-fold and concentrations ranged from 16 ng to 2 g immobilized 
per well. Phages were diluted 2-fold and concentrations ranged from approximately 107 to 109 
particles per well. Purified phage were incubated in each well for 15 min to allow binding. Wells 
were washed and bound phages were detected as described. A plot of absorbance at 450 nm 
versus phage dilution was generated for each target protein concentration. The phage dilution 
and target protein concentration which gave rise to 50% saturation of ELISA signal were used 
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Selection of nanomolar affinity binding proteins for active Tuberculosis diagnosis from an Sso7d 




Tuberculosis (TB) surpassed HIV to be the leading cause of death from infectious disease 
worldwide for the first time in 2014 and caused millions of deaths. The low sensitivity, extended 
processing time and high expense of diagnostics are great challenges to eliminating TB. 
Mycobacterium tuberculosis ornithine transcarbamylase (Mtb OTC, Rv1656) has been identified 
in the urine of patients with active TB infection, making Mtb OTC a promising target for point-of-
care diagnostics in resource-limited settings. We are motivated to engineer phage-based diagnostic 
systems that feature improved physical stability, cost of production and sensitivity relative to 
traditional antibody based reagents. A small, hyperthermophilic and cysteine free DNA-binding 
protein Sso7d was identified as a phage display scaffold for the evolution of tight, specific binding 
molecules that are stable up to 70°C. Specific binding proteins with low nanomolar affinities for 
Mtb OTC were selected from the naïve Sso7d phage library. Phage particles displaying Sso7d 
variants along with a purified monoclonal antibody were utilized to generate a capture ELISA-
based assay for Mtb OTC. The ELISA assay signal is linear over the target concentration range of 
2.0-125.0 ng/mL with limit of detection 0.4 ng/mL (12pM), which is comparable to commercial 
available antibody-based assays (pM~nM sensitivities). Importantly, the assay maintains 
functionality at both neutral and basic pH in presence of salt and urea over the range of 
concentrations typical for human urine. 
  
*This chapter will be published as a paper and 
the contents except abstract are not included in 




A double-phage based diagnostic test established from an Sso7d alternative scaffold phage 




Tuberculosis (TB) has become the leading cause of death from infectious disease. A challenge 
to eliminating this global health issue is lack of effective, efficient and affordable diagnosis at 
point-of-care which is mainly located in resource-poor areas. A fully phage-based diagnostic test 
has the potential to address this global health challenge by detecting a promising protein target 
Mycobacterium tuberculosis ornithine transcarbamylase (Mtb OTC) in urine of TB patients. 
Compared with traditional antibody reagents for protein targets detection, phage has improved 
physical properties especially in thermal stability and therefore phage-based diagnostics have the 
advantage to deliver and store at point-of care without reliable power source. Additionally cost of 
phage production can be reduced to cents per assay, which is critical for undeveloped area 
diagnosis application. A hyperthermophilic protein Sso7d is demonstrated to be evolved into 
sensitive and specific binding molecules against Mtb OTC in chapter 3. In this chapter, a high 
throughput screening methods were developed to select the best pair of Sso7d mutants displaying 
phage particles. As a proof-of-concept, a double-phage capture ELISA utilizing the selected pair 
of phage particles was characterized. This ELISA assay provided a linear response to recombinant 
Mtb OTC between 4.9-625.0 ng/mL (R2=0.9984), with a limit of detection of 4.5 ng/mL (130pM) 
which is comparable with commercial available antibody-based assays. Additionally, this double-
phage capture ELISA assay is quite tolerate with urea, ionic strength and pH in ranges typical to  
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that of human urine, which means this pair of Sso7d binding variants on phage are promising 
candidates for the generation of a diagnostic test for Mtb OTC in a urine matrix. Moreover, the 
tolerance of this double phage-based sensor for pH is significantly improved compared to the 
diagnostic test in chapter 3, which probably due to the replacement of antibody with phage 






 Single chain variable fragment (scFv) based on a monoclonal antibody and displayed on phage 




Antibodies have been served as the quintessential biological recognition molecules for decades. 
Monoclonal hybridoma technology significantly improved applications of antibodies in 
therapeutics and diagnostics. Compared with traditional monoclonal antibody-based diagnostic 
tests, phage-based tests have great advantages in cost, production and stability at harsh conditions. 
For diagnostic applications in resource-limited settings, phage-based diagnostic tests may be 
especially affordable, effective and suitable for point-of-care deployment for the diagnosis of 
infectious diseases, such as tuberculosis (TB). TB remains as a global health issue and in 2014, 
TB has surpassed HIV as the leading cause of death from infectious disease worldwide. The high 
mortality of TB is due primarily to the difficulty of diagnosis in resource-limited areas rather than 
a difficulty in treatment. In order to eliminate the global TB epidemic, fast, sensitive and affordable 
diagnostics of active TB infection are in high demand. A promising diagnostic protein target, 
Mycobacterium tuberculosis ornithine transcarbamylase (Mtb OTC), was identified in urine of TB 
patients, but not in urine of healthy persons. In order to assemble a phage-based assay for detecting 
Mtb OTC, a short version of antibodies, single chain variable fragment (scFv), was converted from 
monoclonal hybridomas prepared against Mtb OTC and displayed on phage surface as binding 
molecules. Binding of the scFv displaying phage particles against the Mtb OTC was evaluated by 
phage ELISA.     
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Table S2-1. List of oligonucleotide primer sequences in chapter 2 
 
Primers Nucleotide sequence 
Oligo 1  5’-CAA CAG TAG CGG CCG CGG CAT GGT GAT GGT GAT G-3’ 
Oligo 2 5’-CTC GAG GCG ACC GTT AAA TTC AAA TAC AAA GGT GAA GAG 
AAA CAG GT-3’ 
Oligo 3 5’-ACA AAG GTG AAG AGA AAC AGG TTG ACA TCT CTA AAA TCT 
GGA TCG TTG CGC-3’ 
Oligo 4 5’-CTA AAA TCT GGA TCG TTG CGC GTG ACG GTA AAT GGA TCG 
ACT TCT CTT ACG-3’ 
Oligo 5 5’-CGA TAC CGG ATT TAC CAC CAC CCA GGT CGT AAG AGA AGT 
CGA TCC ATT TAC-3’ 
Oligo 6 5’-CTT TCG GCG CGT CTT TTT CAG AAA CGT AAC CGA TAC CGG 
ATT TAC CAC CAC-3’ 
Oligo 7 5’-GCT AGC TTT TTT CTG TTT TTC CAG CAT CTG CAG CAG TTC 
TTT CGG CGC GTC TTT TTC-3’ 
Oligo 8 5’-AGC TAG GTC ACT CGA GGC GAC CGT TAA ATT CAA ATA CAA 
AGG T-3’ 
Oligo 9 5’-ACT GAC TTG TGG CTA GCT TTT TTC TGT TTT TCC AGC ATC 
TGC AG-3’ 
Oligo 10 5’-ATT ATT CTC GAG GCG ACC GTT AAA TTC AAA TAC AAA GGT 
G-3’ 
Oligo 11 5’-CGA AAG GGG GAT GTG CTG-3’ 
Oligo 12 5’-ATT ATT GCG CGC ATG CCG CAC TC-3’ 
Oligo 13 5’-CCA CCA CCC AGG TCG TAC CTG AAT CTC CTT CTT TTA CCC 
CTA CGC CTT CTA GAC CAG ATT TTA GAG ATG TCA ACC TGT-3’ 
Oligo 14 5’- GGC GCG TCT TTT TCA GAA ACG NNA CCG NNA CCG NNT 
TTA CCA CCA CCC AGG TCG TAG NNG AAG NNG ATG NNT TTA 
CCG NNA CGG NNA ACG NNC CAG ATT TTA GAG ATG TCA ACC 
TGT TT -3’ 
Oligo 15 5’-CACA TTA GGC ACC CCA G-3’ 
Oligo 16 5’-CAC CAG TAC AAA CTA CAA CGC CTG-3’ 
Oligo 17 5’-ATT ATT CAT ATG GCG ACC GTT AAA TTC AAA TAC AAA GG-3’ 
Oligo 18 







Table S2-2. DNA sequences of Sso7d display features in chapter 2 
 
Feature Nucleotide sequence Protein sequence 
TorA leader peptide 
(TAT) 
5’-ATG AAC AAT AAC GAT CTC TTT CAG GCA 
TCA CGT CGG CGT TTT CTG GCA CAA CTC GGC 
GGC TTA ACC GTC GCC GGG ATG CTG GGG CCC 
TCA TTG TTA ACG CCG CGA CGT GCG ACT GCG 





pelB leader peptide 
(Sec) 
5’- ATG AAA TAC CTA TTG CCT ACG GCA GCC 
GCT GGA TTG TTA TTA CTC GCA GCA AGC GGC 
GCG CAT GCC-3’ 
MKYLLPTAAAGL
LLLAASGAHA 
SRP leader peptide 5’-ATG AAA AAA ATC TGG CTG GCG CTG GCA 




TorA leader and 
Sso7d variant 
5’-GGC GCG CAT GCC GCA CTC GAG-3’ GAHAALE 
Linker between pelB 
leader and Sso7d 
variant 
5’-CTC GAG-3’ LE 
Linker between SRP 
leader and Sso7d 
variant 
5’-CAT GCC GCA CTC GAG-3’ HAALE 
Linker between 
Sso7d variant and p3 
5’-GCT AGC GGC AAA CCA ATC CCA AAC CCA 
CTG CTG GGC CTG GAT AGT ACT CAC CAT CAC 





Sso7d-strep variant 5’-GCG ACC GTT AAA TTC AAA TAC AAA GGT 
GAA GAG AAA CAG GTT GAC ATC TCT AAA ATC 
TGG ATC GTT GCG CGT GAC GGT AAA TGG ATC 
GAC TTC TCT TAC GAC CTG GGT GGT GGT AAA 
TCC GGT ATC GGT TAC GTT TCT GAA AAA GAC 
GCG CCG AAA GAA CTG CTG CAG ATG CTG GAA 














4-parameter Logistic equation 
 
Y: Fraction bound to each well;       
X= [Competitor]; 
A2=Final value. The plateau value when saturated by the competitor and should be close to 0; 
A1=Initial value. The plateau value when very diluted competitor present and should be close 
to 1; 
     P=binding stoichiometry 
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